



Table of Contents

Policy Title	Policy Number	Last Reviewed
Cryosurgery for Prostate Cancer	115	06/15/23
Optilume	672	09/26/23
Pelvic Vein Procedures for Pelvic Congestion Syndrome and Pelvic Varices	268	06/01/23
Penile Implants	611	05/01/23
Percutaneous Renal Nerve Ablation	432	12/28/23
Posterior Tibial Nerve Stimulation (PTNS)	473	06/15/23
Synthetic Bulking Agents for Stress Urinary Incontinence	218	05/01/23
Transurethral Laser Vaporization (TLV) Prostatectomy for Benign Prostatic Hypertrophy (BPH)	229	06/15/23
Transurethral Radiofrequency (RF) for Stress Urinary Incontinence (SUI) [e.g., Renessa]	352	05/01/23
Prostatic Urethral Lift (UroLift) the Treatment of Benign Prostatic Hyperplasia	553	06/15/23
Varicocele Embolization	612	10/19/23



CRYOSURGERY FOR PROSTATE CANCER

Policy # 115

Implementation Date: 3/5/03

Review Dates: 10/23/03, 11/18/04, 11/30/05, 12/21/06, 12/20/07, 2/17/11, 2/16/12, 4/25/13, 2/20/14, 3/19/15, 2/11/16, 2/16/17, 2/15/18, 2/13/19, 6/18/20, 6/17/21, 5/19/22, 6/15/23

Revision Dates: 3/17/06, 5/15/06, 1/12/09, 2/18/10, 3/13/17, 6/1/22

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Prostate cancer is the most common cancer seen in men and is the second most common cause of cancer deaths in men, trailing lung cancer. The number of cases is expected to increase dramatically over the next decade as a result of the aging of the population, as well as improvements in, and access to, methods of diagnosis. Despite the high prevalence of this disease, the management of localized cancer remains controversial, with no standard clinical treatment algorithm. The two most common invasive therapies are radical prostatectomy and external beam radiotherapy. Also, early hormonal therapy and "watchful waiting" are acceptable options. Within the past few years, brachytherapy and cryosurgery have gained attention as alternatives to surgery or radiation. Treatment and prognosis vary dependent upon the stage of cancer.

Cryosurgery of the prostate gland, also known as cryosurgical ablation of the prostate (CSAP), destroys prostate tissue by applying extremely cold temperatures in order to reduce the size of the prostate gland. The ability of cryosurgery to ablate tissue is unquestioned. It is the controlled application of a cryo-injury in a manner that minimizes morbidity that is problematic. This method, like radiation therapy, does not usually destroy the entire prostate gland or all cancer cells within. Five to six cryoprobes are placed transperineally under transrectal ultrasound (TRUS). Once the probes are in place, freezing is carried out while observing under TRUS the increasing echoes as the block of frozen prostate tissue approaches the rectal mucosa. Such monitoring minimizes the risk of rectal freezing. The possibility of injury to the urethra is decreased using a warming device inserted into the urethra. Double- or refreezing is the current standard for killing cancer cells. Hormonal therapy is also often used in conjunction with cryosurgery, especially when the prostate is large.

Prostate cryosurgery is complicated by the proximity of the prostate to adjacent structures that are sensitive to a freeze injury; namely the urethra, rectal wall, and neurovascular bundles. Several recent technological advances have led to the development of an effective treatment protocol with acceptable morbidity. These include the advent of real-time transrectal ultrasound and cryo-machines with almost instant freeze-thaw capabilities.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers cryosurgical ablation for localized prostate cancer, only for salvage therapy in patients with T1-T3 disease. For all other indications, this is considered experimental/investigational.



Cryosurgery for Prostate Cancer, continued

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Cryoablation has been available as a treatment for prostate localized prostate cancer since the early 2000's. Evidence has continued to evolve related to its effectiveness and safety. The technology for the procedure has also evolved and improved outcomes with less peripheral damage resulting in incontinence or impotence have been noted.

There remains limited evidence comparing cryoablation to alternative therapies such as radical prostatectomy and radiation therapy (RT) in the primary or initial treatment setting. In a small trial conducted between 1999 and 2002 by Chin et al., 63 men with T2c or T3 prostate cancer received neoadjuvant ADT and were then randomly assigned to RT or cryotherapy. With a median follow-up of 105 months, the eight-year biochemical disease-free survival was significantly longer for RT compared with cryotherapy (59 versus 17 percent). There was no significant difference in disease-specific or overall survival. Similar findings were identified in a study by Donnelly et al. in 2010 where they studied 244 men with localized prostate cancer and compared their outcomes when randomized to either radiation therapy or cryoablation. All patients had T1-T3 disease. Using the Phoenix criteria to define PSA progression, treatment failure was observed in 24 percent of each treatment group at 36 months. At 36 months there was a higher incidence of positive biopsies in patients treated with RT (29 versus 8 percent), but the significance of a positive biopsy following RT is unclear. The most recent guidelines for the management of localized prostate cancer published by the EUS-ESTRO-SIOG in 2016, note continued lack of evidence with regards to long-term outcomes from cryotherapy, but support at least biological efficacy. However, Siddiqui et al, published a study in October 2016 demonstrating biochemical disease-free survival at 10 and 15 years of 35% and 22.6%, whereas metastasis-free survival at 10 and 15 years of 86% and 71%, respectively. These results suggest durability in treatment of recurrent disease post-radiation treatment.

Focal Cryotherapy: Initial review of the literature identified five case series evaluating focal cryotherapy or "male lumpectomy." These studies concluded that the procedure is effective, though, long-term data are lacking. A more recent review published by McClure et al., in 2017, continues to identify the lack of long-term follow-up in patients undergoing subtotal prostatectomy, as well as the lack of randomized controls comparing to alternative therapies such as radiation therapy or radical prostatectomy.

Overall, the primary weakness of the literature on both cryotherapy applications remains the lack of comparative trials. While cohort studies show some information as to the effectiveness of this therapy in general, only comparative trials would permit conclusions regarding the effectiveness of cryotherapy relative to other common primary therapies for prostate cancer. Interestingly, the only randomized controlled trial concluded that cryotherapy was substantially less effective than external beam radiation. Moreover, while overall morbidity is low following cryotherapy, most studies report high rates of post-operative impotence. Thus, the relative utility of this procedure remains unclear.

Cryosurgery for Prostate Cancer, continued

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

55873 Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring)

HCPCS CODES

C2618 Probe/needle, cryoablation

Key References

1. Babaian RJ, Donnelly B, Bahn D, et al. "Best practice statement on cryosurgery for the treatment of localized prostate cancer." J Urol 180.5 (2008): 1993-2004.
2. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. "Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer." Urology 60 2 Suppl 1 (2002): 3-11.
3. Bahn DK, Silverman P, Lee F, Sr., Badalament R, Bahn ED, Rewcastle JC. "Focal prostate cryoablation: initial results show cancer control and potency preservation." J Endourol 20.9 (2006): 688-92.
4. Ball AJ, Gambill B, Fabrizio MD, et al. "Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution." J Endourol 20.10 (2006): 723-31.
5. Chin JL, Ng CK, Touma NJ, et al. "Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer." Prostate Cancer Prostatic Dis 11.1 (2008): 40-5.
6. Chin JL, Ng CK, Touma NJ, Pus NJ, Hardie R, Abdelhady M, Rodrigues G, Radwan J, Venkatesan V, Moussa M, Downey DB, Bauman G. "Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer." Prostate Cancer Prostatic Dis. 2008;11(1):40.
7. Chin JL, Al-Zahrani AA, Aufran-Gomez AM, Williams AK, Bauman G. "Extended follow-up oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b)." J Urol. 2012;188(4):1170.
8. Cohen JK, Miller RJ, Jr., Ahmed S, Lotz MJ, Baust J. "Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy." Urology 71.3 (2008): 515-8.
9. Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D. "Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease." BJU Int 97.5 (2006): 969-74.
10. Donnelly BJ, Saliken JC, Brasher PM, Ernst SD, Rewcastle JC, Lau H, Robinson J, Trpkov K. "Cancer 2010;116(2):323
11. Donnelly BJ, Saliken JC, Ernst DS, et al. "Prospective trial of cryosurgical ablation of the prostate: five-year results." Urology 60 4 (2002): 645-9.
12. El Hayek OR, Alfer W, Jr., Reggio E, et al. "Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes." Urol Int 81.2 (2008): 186-90.
13. El Hayek OR, Alfer W, Jr., Reggio E, Pompeo AC, Arap S, Srougi M. "Percutaneous prostate cryoablation as treatment for high-risk prostate cancer." Clinics 62.2 (2007): 109-12.
14. Ellis DS, Manny TB, Jr., Rewcastle JC. "Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results." Urology 70.6 Suppl (2007): 9-15.
15. Hayes Directory. Cryoablation for prostate cancer. 2006. Winifred S. Hayes, Inc. Date Accessed: November 5, 2008.
16. Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. "Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry." J Urol 180.2 (2008): 554-8.
17. Lambert EH, Bolte K, Masson P, Katz AE. "Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer." Urology 69.6 (2007): 1117-20.
18. McClure TD, Margolis DJ, Hu JC. "Partial gland ablation in the management of prostate cancer: a review. Curr Opin Urol Mar;27(2): 156-160.
19. Mottet, N. et al, "EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and Local Treatment with Curative Intent. Eur Urol Apr;71(4): 618-629
20. Mouraviev V, Nosnik I, Sun L, et al. "Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience." Urology 69.2 (2007): 311-4.
21. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. "Male lumpectomy": focal therapy for prostate cancer using cryoablation." Urology 70.6 Suppl (2007): 16-21.
22. Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J. "The 'male lumpectomy': focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up." Urol Oncol 26.5 (2008): 500-5.
23. Onik G. "Rationale for a 'male lumpectomy,' a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up." Cardiovasc Intervent Radiol 31.1 (2008): 98-106.
24. Polascik TJ, Mayes JM, Mouraviev V. "From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer." Oncology (Williston Park) 22.8 (2008): 900-6; discussion 906-7, 914.
25. Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. "Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology." Urology 70.1 (2007): 117-21.
26. Prepelica KL, Okeke Z, Murphy A, Katz AE. "Cryosurgical ablation of the prostate: high risk patient outcomes". Cancer 103 8 (2005): 1625-30.
27. Savarese DM, Kupelian P, Klein EA. "Overview of treatment for early prostate cancer". UpToDate Online www.uptodate.com (2006).
28. Shelley M, Wilt TJ, Coles B, Mason MD. "Cryotherapy for localised prostate cancer." Cochrane Database Syst Rev.3 (2007): CD005010.

Genitourinary Policies, Continued

Cryosurgery for Prostate Cancer, continued

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health[®] makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



OPTILUME

Policy # 672

Implementation Date: 9/26/23

Review Dates:

Revision Dates: 12/14/23

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Urethral stricture (US) is an abnormal narrowing of the urethra that can be caused by acute injury, inflammation, postsurgical complications, infections, and cancer. Though urethral strictures can occur in either sex, they are rare in female persons. The incidence rate of US in the United States is 0.9% annually, resulting in 1.5 million hospital visits every year. US can be anterior or posterior with anterior US comprising 92% of cases. Symptoms include decreased urinary stream, incomplete emptying, dysuria, bloody or dark urine, urethral leaking, and urinary tract infection.

Treatment options for urethral strictures depend on the site, length, etiology, and whether it is primary or recurrent. Common treatments include urethroplasty, urethral dilation, urinary diversion procedures, and direct visual internal urethrotomy (DVIU). Urethroplasty is considered the reference standard for treatment, but it is more invasive than endoscopic treatments, and can be associated with complications of sexual dysfunction, neuropathy, and pain. Endoscopic treatments such as mechanical dilation and DVIU are associated with high recurrence rates, especially after retreatment. Repeated endoscopic interventions may lead to cumulative injury, lengthening of strictures, and ultimately impairment of urethroplasty success. Recurrent strictures and those undergoing repeat endoscopic treatment are considered high-risk, with low success rates for repeat endoscopic treatment.

The Optilume urethral drug-coated balloon (DCB) (Laborie) is a medical device used for treatment and management of US. It exerts radial force to dilate narrow urethral segments (strictures) while slowing or stopping the stricture formation and includes a drug coating which prevents additional stricture.

Optilume is designed to treat urethral strictures that are ≤ 3 centimeters (cm) long in adult males. The device is inserted into the urethra and advanced to the site of the stricture during an outpatient procedure. Once in position, the balloon is inflated, exerting radial force to dilate the narrow urethral segment. The drug coating on the balloon is released into the surrounding tissue to limit cell proliferation and prevent the formation of fibrotic scar tissue, which can cause stricture recurrence. The catheter is designed to reduce the risk of tissue trauma or perforation during insertion and positioning (U.S. Food and Drug Administration [FDA], 2021).

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers implantation of the Optilume drug coated balloon when all the following criteria are met:

1. Member ≥ 18 years of age; and



Genitourinary Policies, Continued

Optilume, continued

2. Member has urinary symptoms associated with urethral stricture; and
3. Member has urethral stricture of ≤ 3 cm in length; and
4. Member has recurrent bulbar urethral strictures.

Select Health does not cover any repeat applications of Optilume as there is insufficient data to support safety and efficacy; this meets the plan's definition of experimental/investigational.

Contraindications:

The Optilume Urethral Drug Coated Balloon is contraindicated for use in patients with known hypersensitivity to paclitaxel or structurally related compounds, and in patients with urologic implants such as penile implants or artificial urinary sphincters.

Select Health Advantage (Medicare/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

Select Health Community Care (Medicaid)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Billing/Coding Information

CPT CODES

0499T Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed

Key References

1. Hayes, Inc. Evidence Analysis Research Brief. Optilume Urethral Drug-Coated Balloon (Latorie) for Treatment of Urethral Strictures. May 10, 2023.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Genitourinary Policies, Continued

Optilume, continued

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



PELVIC VEIN PROCEDURES FOR PELVIC CONGESTION SYNDROME AND PELVIC VARICES

Policy # 268

Implementation Date: 3/5/05

Review Dates: 1/26/06, 2/15/07, 2/21/08, 2/26/09, 2/17/11, 2/16/12, 4/25/13, 2/20/14, 3/19/15, 2/11/16, 2/16/17, 2/15/18, 2/4/19, 8/20/20, 6/17/21, 5/19/22, 6/1/23

Revision Dates: 2/18/10, 11/23/15

Related Medical Policies:

[#193 Varicose Vein Procedures](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Pelvic congestion syndrome (PCS) is caused by utero-ovarian varices. It is the sole cause of pain in 30% of outpatients presenting with chronic pelvic pain, a condition that accounts for approximately 15% of outpatient gynecologic visits in the United States. Pelvic congestion syndrome is defined by visibly engorged pelvic veins of more than 10 mm in diameter on selective transuterine venography in multiparous, premenopausal women with a history of chronic, noncyclic pelvic pain for more than 6 months. Nulliparous women may also be affected, although this is uncommon. Patients may report pelvic pain in the following situations:

- when standing or in the upright position (relieved in the supine position)
- during or after intercourse
- in association with varices in the thigh, buttock, perineum, vulva, or vagina
- in association with bladder urgency

The symptoms may increase after giving birth. Differential diagnoses include endometriosis, pelvic adhesions, chronic pelvic inflammatory disease, fibroids, pelvic floor muscle pain, urologic disorders, irritable bowel syndrome, and psychosocial issues.

Partial suppression of ovarian function with medroxyprogesterone acetate may relieve symptoms in some patients with PCS. Psychotherapy is sometimes used as an adjunct treatment. Patients who do not respond to pharmacological treatment and/or psychotherapy, or who experience recurrence of symptoms, may be referred for surgical therapies, including ovarian vein ligation or hysterectomy with removal of one or both ovaries. However, surgical therapies are associated with significant morbidity, and hysterectomy may be undesirable, especially in younger women who desire children.

Several procedures are also performed to treat pelvic congestion/pelvic varicosities. One such treatment is percutaneous transcatheter coil embolization. This has been proposed as an alternative treatment strategy to surgery and as an adjunct procedure to embolization with detachable balloons, sclerosing agents, or glue (e.g., embucrilate). Percutaneous access to the ovarian vein is generally gained via the femoral venous approach. Several coils are inserted into the affected ovarian vein under fluoroscopic guidance, using contrast media to locate the varices. The ovarian and internal iliac veins are in close communication, therefore, in some cases, embolization of the iliac veins may also be required. Embolization of the iliac vein is usually performed after treatment of the ovarian vein.

Foam sclerotherapy is another procedure sometimes performed and using an intravascular foam which scars the vessels (scleroses) closed. It has been found to be safe and effective treatment for high-flow

Pelvic Vein Procedures for Pelvic Congestion Syndrome and Pelvic Varices, continued

female varicoceles and should be considered as an alternative to other endovascular and surgical options.

Percutaneous transcatheter with coils, plugs, or sclerotherapy, usually as combination treatment, has become the standard approach for management of both pelvic congestion syndrome and varices arising from a pelvic source.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers treatment of pelvic congestion syndrome and pelvic varices using coil embolization, plugs, or transcatheter sclerotherapy, alone or in combination, when the following criteria are met.

1. Pelvic Congestion Syndrome:
 - A. Pelvic pain of at least six months duration without other etiology.
 - B. Imaging consistent with pelvic venous changes.
 - C. Have tried and failed conservative therapy.
2. Pelvic/Labial Varicosities: (Documentation must demonstrate all the following):
 - A. The patient is unable to perform ADLs (activities of daily living) such as feeding, bathing, dressing, grooming, meal preparation, house chores, and occupational tasks for functioning.
 - B. Patient has failed to respond to conservative therapy of at least 3 months duration; conservative therapy must include use of prescription anti-inflammatories, unless contraindicated.
 - C. Varicose veins to be treated must be 4mm or greater in diameter.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

A search of the peer-reviewed medical literature identified 3 very small case series studies and 1 larger randomized comparative clinical trial investigating the efficacy and safety of coil embolization of the ovarian vein for the treatment of PCS. Small sample sizes, lack of control groups, insufficiently defined patient selection criteria, non-standardized procedures, and the predominant use of patient self-assessed

Pelvic Vein Procedures for Pelvic Congestion Syndrome and Pelvic Varices, continued

subjective outcome measures compromised the quality of most of the studies. In addition, the case series used only 1 instrument to assess outcomes.

The 3 case series studies included 6–11 patients, and the randomized study included 106 patients. Clinical diagnosis was confirmed with selective venography. Relief of symptoms was the only outcome measure and was assessed using standardized questionnaires or a visual analogue scale. Patients were followed for between 3 months and 4 years.

Initial technical success rates were determined by using repeat angiography and ranged from 88.9%–100%. The treatment effect varied considerably among and within studies, and symptom relief ranged from 40%–100%. In 1 very small case series study (n = 6), the treatment effect was maintained for all patients for 1–4 years, whereas a second case series study reported recurrence in 1 patient at 6 months and 1 at 22 months.

The only randomized trial compared the efficacy of coil embolization (group 1, n = 52) with hysterectomy and bilateral oophorectomy (group 2, n = 27) or hysterectomy and unilateral oophorectomy (group 3, n = 27). Furthermore, patients were stratified according to stress scores (using a social readjustment rating scale) into 3 subgroups; normal, moderate high, and very high stress levels. A significant improvement in pain symptoms versus baseline values were observed for patients in all 3 groups. Patients with normal to moderate high stress levels who received coil embolization experienced superior symptom relief compared with patients who underwent hysterectomy with unilateral or bilateral oophorectomy. However, patients with very high stress levels did not derive as much treatment benefit as patients with normal to moderate high stress levels. The treatment effect was maintained for 12 months in all patients.

The preliminary evidence indicates that coil embolization of the ovarian vein is a relatively safe procedure that causes only minor, transient side effects (e.g., hematoma at the percutaneous access site and slightly elevated temperature). Coil embolization of the ovarian vein should not be performed in patients with significant contraindications to venography or endovascular procedures, or who have sensitivities/allergies to contrast material. Some investigators caution against the use of coil embolization in the internal iliac veins since emboli may be dislodged and carried to the lungs, causing pulmonary emboli.

In a study by Machan, et al., ovarian and pelvic vein embolization was performed in 22 women with chronic pelvic congestion and angiographical demonstrated ovarian varicosities. In 10 cases, embolization produced complete resolution of symptoms, while partial resolution was achieved in another 6 cases. Six patients experienced no improvement. That study demonstrated that, in properly selected and screened patients, embolization is a safe and effective treatment for pelvic congestion syndrome.

Billing/Coding Information

Covered: *For the conditions outlined above*

CPT CODES

- | | |
|--------------|---|
| 37241 | Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles) |
| 75894 | Transcatheter therapy, embolization, any method, radiological supervision and interpretation |

HCPCS CODES

No specific codes identified

Key References

1. Bachar GN, Belenky A, Greif F, et al. Initial experience with ovarian vein embolization for the treatment of chronic pelvic pain syndrome. *Isr Med Assoc J.* 2003;5(12):843-846.
2. Beard RW, Kennedy RG, Gangar KF, Stones RW, Rogers V, Reginald PW, et al. Bilateral oophorectomy and hysterectomy in the treatment of intractable pelvic pain associated with pelvic congestion. *British Journal of Obstetrics and Gynecology* 1991, 98:988-992.
3. Capasso P, Simons C, Trotteur G, Dondelinger RF, Henroleaux D, Gaspard U. Treatment of Symptomatic Pelvic Varices by Ovarian Vein Embolization. *Cardiovasc Intervent Radiol* 1997; 20:107-111.

Pelvic Vein Procedures for Pelvic Congestion Syndrome and Pelvic Varices, continued

4. Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. *Tohoku J Exp Med.* 2003;201(3):131-138.
5. Cordis PR, Eclavea A, Buckley PJ, DeMaiores A, Cockerill ML, Yeager TD. Pelvic Congestion Syndrome: Early Clinical Results after Transcatheter Ovarian Vein Embolization. *J Vasc Sug* 1998; 28:862-868.
6. Edwards RD, Robertson JR, MacLean AB, Hemingway AP. Case Report: Pelvic Pain Syndrome-Successful Treatment of a Case by Ovarian Vein Embolization. *Clin Radiol* 1993; 47:429-431.
7. Gandini, R., et al. (2014). "Treatment of symptomatic high-flow female varicoceles with stop-flow foam sclerotherapy." *Cardiovasc Intervent Radiol* 37(5): 1259-1267.
8. Gloviczki, P., et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society of Vascular Surgery and the American Venous Forum. *J Vascular Surgery*, 2011-05-01, 53, 2s-48s.
9. Halligan S, Campbell D, Bartram CI, et al. Transvaginal ultrasound examination of women with and without pelvic venous congestion. *Clin Radiol.* 2000;55(12):954-958.
10. Hayes Alert. Technology Brief. Coil Embolization of the Ovarian Vein for Pelvic Congestion Syndrome. Vol 10, Oct 2004.
11. Hobbs JT. The pelvic congestion syndrome. *British Journal of Hospital Medicine* 1990; 43:2000:2006.
12. Machan LS, Doyle L, Fry P. Treatment of chronic pelvic congestion syndrome by ovarian vein embolization. Presented at the annual meeting of Cardiovascular and Interventional Radiological Society of Europe (CIRSE, Madeira, Portugal, September/96.
13. Maleux G, Stockx L, Wilms G, Marchal G. Ovarian Vein Embolization for the Treatment of Pelvic Congestion Syndrome: Long-term Technical and Clinical Results. *J Vasc Interv Radiol* 2000; 11:859-864.
14. Pieri S, Agresti P, Morucci M, de' Medici L. Percutaneous Treatment of Pelvic Congestion Syndrome. *Radiology Med* 2003;105(1-2); 76-82
15. Reyes BL, Trerotola SO, Venbrux AC, et al. Percutaneous Embolotherapy of Adolescent Varicocele: Results and Long-term Follow-up. *J Vasc Interv Radiol* 1994; 5:131-134.
16. Sichlau MU, Yao JST, Vogelzang L. Transcatheter Embolotherapy for the Treatment of Pelvic Congestion Syndrome. *Obstet Gynecol* 1994; 83:892-896.
17. Stones RW, Mountfield J. Interventions for Treating Chronic Pelvic Pain in Women. *Cochrane Database Syst Rev* 2000;(2):CD000387.
18. Tarazov PC, Prozorovakji KY, Ryzhov VK. Pelvic Pain Caused by Ovarian Varices: Treatment of Transcatheter Embolization. *Acta Radiol* 1997; 98:1023-1025.
19. The International Pelvic Pain Society/02.
20. Venbrux AC, Lambert DL. Embolization of the ovarian veins as a treatment for patients with chronic pelvic pain caused by pelvic venous incompetence (pelvic congestion syndrome). *Curr Opin Obstet Gynecol* 1999; 11:395-399.
21. Venbrux AC, Lambert DL. Ovarian and Pelvic Varices in the Female Patient. In Savader SJ, Trerotola SO, eds. *Venous Interventional Radiology with Clinical Perspectives.* New York: Thieme 2000; 210-216.
22. Venbrux AC, Trerotola SO. Transcatheter Embolotherapy of Varicoceles. *Semin Interv Radiol* 1994; 11:305-311.
23. Venbrux AC, et al. Pelvic Congestion Syndrome (Pelvic Venous Incompetence): Impact of Ovarian and Internal Iliac Vein Embolotherapy on Menstrual Cycle and Chronic Pelvic Pain. *Journal of Vascular and Interventional Radiology* 2002, 13:171-178.
24. Zuckerman AM, Mitchell SE, Venbrux AC, et al. Percutaneous Varicocele Occlusion: Longer-term Follow-up. *J Vasc Interv Radiol* 1994; 5:315-319.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and of Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



PENILE IMPLANTS

Policy # 611

Implementation Date: 4/27/17

Review Dates: 7/16/18, 4/17/19, 4/13/20, 4/15/21, 3/11/22, 5/1/23

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Male Erectile Dysfunction (ED) is defined as the inability of a man to attain and maintain an erection sufficient for sexual intercourse. ED may be organic in nature, which is, caused by a detectable physiological or structural change, or may be psychologically related to underlying behavioral health issues. For more severe disease, usually associated with advanced diabetes, surgical or radiation treatment for prostate or bladder cancer, or Peyronie's disease, implantation of a penile prosthesis is a therapeutic alternative.

Penile implants are devices placed inside the penis to allow men with erectile dysfunction (ED) to get an erection. There are three basic kinds of penile implants: semi-rigid (malleable) implant, two-piece inflatable implant, and three-piece inflatable implant.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does NOT cover penile implants as a standard benefit. Only plans with a sexual dysfunction rider will cover penile implants, when the following criteria are met:

1. The history and physical exam of the member are consistent with sexual dysfunction.
 - a) The member has a medical (organic) condition that directly contributes to sexual dysfunction; **and**
 - b) Appropriate covered medical therapies have been tried and failed, such as testosterone replacement therapy, if appropriate, or intracavernous apastradil injections, suppositories, or PDE5 inhibitors.
2. Replacements of a penile implant are covered if:
 - a) The device malfunctions, breaks, or becomes infected; **and**
 - b) Medically necessity criteria continue to be met; **and**
 - c) Replacement is not part of the manufacturer's warranty.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)



Penile Implants, continued

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The American Urological Association (AUA) *Guideline on the Management of Erectile Dysfunction: Diagnosis and Treatment Recommendations* defines the index case of ED as the absence of hypogonadism or hyperprolactinemia in a man who develops, after a well-established period of normal erectile function, ED that is primarily organic in nature (AUA, 2005, Update 2007). The European Association of Urology (EAU) defines ED as the: "Persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance" (Hatzimouratidis, 2015).

The AUA (2007) guidelines note: "Cardiovascular disease and ED may share a common etiology when endothelial dysfunction and atherosclerosis affect both coronary arteries and penile vasculature." The EAU guideline notes: "ED shares both unmodifiable and modifiable common risk factors with CVD (e.g., obesity, diabetes mellitus, dyslipidemia, metabolic syndrome, lack of exercise, and smoking)" (Hatzimouratidis, 2015). The Princeton guideline for sexual medicine addresses sexual dysfunction and cardiac risk, and was updated in 2006, with the publication of the second consensus statement. The guideline noted individuals with no known cardiovascular disease but presenting with ED may have other comorbidities (e.g., diabetes, hypertension, hyperlipidemia, heart disease) (Jackson, 2006).

The AUA (2007) guideline update for erectile dysfunction states:

The management of erectile dysfunction begins with the identification of organic comorbidities and psychosexual dysfunctions; both should be appropriately treated, or their care triaged. The currently available therapies that should be considered for the treatment of erectile dysfunction include the following: oral phosphodiesterase type 5 [PDE5] inhibitors, intra-urethral alprostadil, intracavernous vasoactive drug injection, vacuum constriction devices, and penile prosthesis implantation. These appropriate treatment options should be applied in a stepwise fashion with increasing invasiveness and risk balanced against the likelihood of efficacy.

The EAU guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation (Hatzimouratidis, 2015) recommend the implanted penile prosthesis as a third-line of therapy for individuals that have failed other non-surgical treatments. As the placement of a penile prosthesis requires the dislocation of cavernosal tissue, it is considered a permanent and irreversible procedure that should be reserved in those who have failed or are intolerant of conservative measures (Trost, 2016).

Damage to nerves, arteries, smooth muscles, and fibrous tissues, often as a result of disease, is the most common cause of ED. Vascular disease and neurologic disease account for about 70% of ED cases. Between 35 and 50 percent of men with diabetes experience ED. Surgery (especially radical prostate and bladder surgery for cancer) and radiotherapy can injure nerves and arteries near the penis, causing ED (AUA, 2007; Chung, 2014; NCCN, 2015). Injury to the penis, spinal cord, prostate, bladder, and pelvis can lead to ED by harming nerves, smooth muscles, arteries, and fibrous tissues of the corpora cavernosa.

Use of a penile prosthesis is an established technique for treating male impotence due to neurogenic or vasculogenic disease processes after failure of less invasive medical treatments with approximately 20,000 procedures performed annually (AUA, 2007; Chung, 2014; Hatzimouratidis, 2015; Lee, 2015). Penile implants involve surgical insertion of malleable or inflatable rods or tubes into the penis. The surgery is not without possible complications. Minervini and colleagues (2006) studied 447 men who had 504 penile prosthetics implanted and found that infection was the most frequent complication. Other complications were implant migration and tissue erosion. In a review by Phé (2012), the rate of infection had decreased to 1% with the utilization of antibiotic impregnated implants.

Zermann and colleagues (2006) studied 245 neurologically impaired men who had penile prosthetics implanted. There were 3 groups based on the indication for penile prosthetic surgery. Group 1 consisted

Penile Implants, continued

of 134 participants with urinary management only, Group 2 had 60 participants with erectile dysfunction only, and Group 3 had 51 participants with urinary management and erectile dysfunction. At a mean follow-up of 7.2 years (maximum 17 years), 195 participants were reevaluated in the clinic. Outcomes showed that in 122 participants (90.3%), urinary management problems were resolved, and erectile dysfunction treatment was successful in 76 participants (82.6%). Forty-three revisions were performed for complications (e.g., infections and device perforation). The U.S. Food and Drug Administration (FDA) considers the rigid penile implant as a Class II device. The semi-rigid rods are implanted into the corpora cavernosa of the penis to provide rigidity. Inflatable penile implants are considered Class III devices by the FDA. Inflatable cylinders are implanted in the penis and are connected to a reservoir filled with fluid implanted in the abdomen, and a subcutaneous manual pump implanted in the scrotum. Penile rigidity is achieved when the cylinders are filled with fluid.

Billing/Coding Information

CPT CODES

54115	Removal foreign body from deep penile tissue (eg, plastic implant)
54400	Insertion of penile prosthesis; non-inflatable (semi-rigid)
54401	Insertion of penile prosthesis; inflatable (self-contained)
54405	Insertion of multi-component, inflatable penile prosthesis, including placement of pump, cylinders, and reservoir
54408	Repair of component(s) of a multi-component, inflatable penile prosthesis
54410	Removal and replacement of all component(s) of a multi-component, inflatable penile prosthesis at the same operative session
54411	Removal and replacement of all components of a multi-component inflatable penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue
54415	Removal of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis, without replacement of prosthesis
54416	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis at the same operative session
54417	Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue

HCPCS CODES

C1813	Prosthesis, penile, inflatable
C2622	Prosthesis, penile, noninflatable
L8699	Prosthetic implant, not otherwise specified

Key References

1. American Association of Clinical Endocrinologists (AACE) Male Sexual Dysfunction Task Force. Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Male Sexual Dysfunction: A couple's problem. 2003 Update. Available at: <https://www.aace.com/files/sexdysguid.pdf>. Accessed on May 25, 2016.
2. American Urological Association (AUA)
3. Carson CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011; 185(2):614-618.
4. Centers for Medicare and Medicaid Services. National Coverage Determination: Diagnosis and Treatment of Impotence. NCD #230.4. Effective date not posted. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/ncd-by-chapter-and-section-index.aspx?bc=AgAAAAAAAAAA&>. Accessed on May 31, 2015.
5. Chung E, Gilliman M. Prostate cancer survivorship: a review of erectile dysfunction and penile rehabilitation after prostate cancer therapy. Med J Aust. 2014; 200(10):582-585.
6. CMS MLN Matters SE1511, Discontinued Coverage of Vacuum Erection Systems (VES) Prosthetic Devices in Accordance with the Achieving a Better Life Experience Act of 2014. Accessed online on 07/06/2015.

Penile Implants, continued

7. Darouiche RO, Bella AJ, Boone TB, et al, Christine B, Dhabuwala CB, Hakim LS, Henry G, Jones LA, Khera M, Montague DK, Nehra A. North American consensus document on infection of penile prostheses. *Urology*. 2013; 82(4):937-942.
8. Guideline on the management of erectile dysfunction: an update. 2005/Update 2007. Reviewed 2011. Available at: <http://www.auanet.org/common/pdf/education/clinical-guidance/Erectile-Dysfunction.pdf>. Accessed on May 25, 2016.
9. Hatzimouratidis, Eardley I, Giuliano D, et al. European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. *Eur Urol*. 2015. Available at: <http://uroweb.org/guideline/male-sexual-dysfunction/>. Accessed on May 25, 2016.
10. Hellstrom WJ, Montague DK, Moncada I, et al. Implants, mechanical devices and vascular surgery for erectile dysfunction. *J Sex Med*. 2010; 7(1 Pt 2):501-523.
11. Henry GD, Wilson SK. Updates in inflatable penile prostheses. *Urol Clin North Am*. 2007; 34(4):535-547.
12. Israilov S, Shmueli J, Niv E, et al. Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. *Int J Impot Res*. 2005; 17(5):431-436.
13. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. *J Sex Med*. 2006; 3(1):28-36.
14. Lee DJ, Najari BB, Davison WL, et al. Trends in the Utilization of Penile Prostheses in the Treatment of Erectile Dysfunction in the United States. *J Sex Med*. 2015; 12(7):1638-1645.
15. Medicare National Coverage Determination for Diagnosis and Treatment of Impotence (ID #230.4); Effective date: Longstanding determination - effective date not posted; Accessed on 07/07/2015 via Internet site www.cms.gov/mcd/viewnacd
16. Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. *BJU Int*. 2006; 97(1):129-133.
17. Mulcahy JJ, Austoni E, Barada JH, et al. The penile implant for erectile dysfunction. *J Sex Med*. 2004; 1(1): 98-109.
18. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Erectile Dysfunction. November 2015. Available at: <http://www.kidney.niddk.nih.gov/KUDiseases/pubs/ED/index.aspx>. Accessed on August 11, 2016.
19. NCCN Clinical Practice Guidelines in Oncology®. ©2016 National Comprehensive Cancer Network, Inc. Prostate Cancer. V.3.2016. Revised May 26, 2016. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on August 11, 2016.
20. Ong WL, Hindson BR, Beaufort C, et al. Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. *Radiother Oncol*. 2014; 112(1):72-76.
21. Peyronie's Disease: AUA Guideline. 2015. Available at: <https://www.auanet.org/common/pdf/education/clinical-guidance/Peyronies-Disease.pdf>. Accessed on May 25, 2016.
22. Phé V, Roupêt M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. *Diabetes Metab*. 2012; 38(1):1-13.
23. Selph JP, Carson CC. Penile prosthesis infection: approaches to prevention and treatment. *Urol Clin North Am*. 2011; 38(2):227-235.
24. Stember DS, Mulhall JP. The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer. *Brachytherapy*. 2012; 11(2):87-96.
25. Stephenson RA, Mori M, Hsieh YC, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the surveillance, epidemiology and end results prostate cancer outcomes study. *J Urol*. 2005; 174(2):646-650.
26. The Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. *Int J Impot Res*. 1999; 11(2):59-74. Retrieved from: <http://www.nature.com/ijir/journal/v11/n2/pdf/3900411a.pdf>
27. Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. *Nat Rev Urol*. 2016; 13(1):33-46.
28. Zemann DH, Kutzenberger J, Sauerwein D, et al. Penile prosthetic surgery in neurologically impaired patients: long-term follow-up. *J Urol*. 2006; 175(3 Pt 1):1041-1044.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and of Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



PERCUTANEOUS RENAL NERVE ABLATION

Policy # 432

Implementation Date: 12/27/09

Review Dates: 4/28/10, 5/19/11, 6/21/12, 10/24/13, 10/23/14, 10/15/15, 10/20/16, 10/19/17, 10/3/18, 10/15/19, 10/15/20, 11/18/21, 9/15/22, 12/28/23

Revision Dates: 9/28/12

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

According to the National Health and Nutritional Examination Survey (NHANES) 2005–2006 data set it has been estimated that overall, 29% of adults aged 18 years and older has hypertension. The prevalence of hypertension did not change during 1999–2006. Among hypertensives, 78% were aware of their hypertension and 68% were taking antihypertensive medication. Among those taking medication, 64% had controlled BP (under 140/90 mmHg).

Hypertension is classified based upon the average of 2 or more properly measured readings at each of 2 or more visits after an initial screen. This is further classified as:

- Normal blood pressure: systolic < 120 mmHg and diastolic < 80 mmHg
- Prehypertension: systolic 120–139 mmHg or diastolic 80–89 mmHg
- Hypertension:
 - Stage 1: systolic 140–159 mmHg or diastolic 90–99 mmHg
 - Stage 2: systolic \geq 160 or diastolic \geq 100 mmHg

These definitions apply to adults on no antihypertensive medications and who are not acutely ill. If there is a disparity in category between the systolic and diastolic pressures, the higher value determines the severity of the hypertension. The systolic pressure is the greater predictor of risk in patients over the age of 50–60.

Some patients have hypertension seemingly resistant to conventional medical therapy. This is usually defined as failure to achieve goal blood pressure (BP) despite adherence to an appropriate 3-drug regimen including a diuretic. In most patients, the blood pressure goal is less than 140/90 mmHg and less than 130/80 mmHg in those with diabetes, proteinuric chronic kidney disease, or coronary artery disease or a coronary equivalent.

It is postulated that renal sympathetic efferent and afferent nerves are crucial for the initiation and maintenance of systemic hypertension. It has been proposed that catheter-based radiofrequency ablation of renal sympathetic nerves may lower the blood pressure in patients with resistant hypertension. The nerves lie within and immediately adjacent to the wall of the renal artery. During the procedure, the tip of the catheter is directed into the distal renal artery and 2 minutes of RF energy is applied. The tip is withdrawn, circumferentially rotated within the artery, and a further two minutes of energy is applied, and so on all the way back through the renal artery, with a cumulative 4–6 applications of the RF energy.



Percutaneous Renal Nerve Ablation, continued

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does **NOT** cover percutaneous renal nerve ablation. There is limited literature and research on this technology; this meets the plan's definition of experimental/investigational.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

In a Medical Technology Assessment completed by SelectHealth in October 2009, there was only 1 proof-of-concept study that met criteria for review. This 2009 study by Krum et al. evaluated 50 patients with resistant hypertension (systolic pressure \geq 160 mmHg [mean 177/101 mmHg] on 3 or more antihypertensive medications) who underwent percutaneous radiofrequency catheter-based treatment. The treatment led to reductions in systolic blood pressure of more than 10 mmHg in 39 of 45 patients, with mean reductions in blood pressure of 14/10, 21/10, 22/11, 24/11, and 27/17 mmHg at 1, 3, 6, 9, and 12 months respectively. In contrast, the mean blood pressure increased by 26/17 mmHg at 9 months in the 5 patients who were excluded from sympathectomy for anatomical reasons. Complications of the intervention included 1 renal artery dissection and 1 femoral artery pseudoaneurysm.

This study suggests some potential for this procedure in treating resistant hypertension. However, a single study is insufficient to determine whether the procedure is safe and effective, particularly over the long-term. Likewise, patient selection criteria and contraindications cannot be clearly identified through this single study. Additional research is needed to address such concerns before percutaneous renal artery ablation can be considered a legitimate treatment for treatment resistant hypertension.

The National Institute for Health and Clinical Excellence (NICE) in the UK published an Interventional Procedure Guidance in January 2012. They could only identify evidence on a limited number of patients on a short- or medium-term basis, but no long-term data could be identified. The limited data did suggest a low incidence of serious complications, but the evidence was inadequate for long-term safety. NICE noted though treatment of drug-resistant hypertension may be difficult, and sympathetic denervation of the renal artery is promising, a larger number of evidence-based, well-designed trials are required to determine its safety and efficacy.

Billing/Coding Information

Not covered: Investigational/Experimental/Unproven for this indication

CPT CODES

0338T Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral

Percutaneous Renal Nerve Ablation, continued

- 0339T** Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral

HCPCS CODES

No specific codes identified

Key References

1. Ardian I. (2009). The Symplicity® Catheter System. Medscape. Available: <http://www.ardian.com/medical-professionals/system.shtml>. Date Accessed: November 2, 2009.
2. Barbanti, M., et al. (2012). "Transcatheter aortic valve implantation in patients with mitral prosthesis." *J Am Coll Cardiol* 60(18): 1841-1842.
3. Domino FJ, Kaplan NM. (2009). Overview of hypertension in adults. UpToDate. Date Accessed: November 2, 2009.
4. Jeffery S. (2009). ACC, 2009: Catheter-Based Renal Denervation Reduces Resistant Hypertension. Medscape. Available: <http://www.medscape.com/viewarticle/590320>. Date Accessed: November 2, 2009.
5. Krum H, Schlaich M, Whitbourn R, et al. (2009). Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet* 373.9671: 1275-81.
6. National Institute of Clinical Excellence (NICE), UK. (2012). Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension. National Institute of Clinical Excellence (NICE), UK. January.
7. Ostchega Y, Yoon SS, Hughes J, Louis T. (2008). Hypertension Awareness, Treatment, and Control - Continued Disparities in Adults: United States, 2005-2006. No. 3. January 2008. National Health and Nutritional Examination Survey. Available: <http://www.cdc.gov/nchs/data/databriefs/db03.pdf>. Date Accessed: November 11, 2009.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



POSTERIOR TIBIAL NERVE STIMULATION (PTNS)

Policy # 473

Implementation Date: 12/13/10

Review Dates: 12/15/11, 12/19/13, 12/18/14, 8/17/17, 7/16/18, 6/20/19, 6/18/20, 6/17/21, 5/19/22, 6/15/23

Revision Dates: 12/11/12, 7/21/16, 2/19/21, 6/9/22

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Overactive bladder (OAB) is a problem with bladder storage function that causes a sudden urge to urinate. The urge may be difficult to suppress, and overactive bladder can lead to the involuntary loss of urine (incontinence). The overactive bladder is defined as urgency, with or without urge incontinence, usually with frequency and abnormally excessive urination during the night (nocturia).

Behavioral therapy and operative procedures may be used to treat OAB, but pharmacologic therapy remains first-line treatment. The medications used to treat overactive bladder problems are antimuscarinic and anticholinergic receptor inhibitors which block the effect of nerve signals coming to, or originating within the bladder, causing the muscles of the bladder to relax.

Percutaneous posterior tibial nerve stimulation (PTNS) uses the concept of neuromodulation to inhibit the urge to urinate. There is not a complete understanding of the exact mechanisms of how PTNS works but it is thought that by inhibiting a nerve entering the spinal cord near the exit point of the nerves going to the bladder, these nerves are also inhibited.

The procedure for PTNS consists of the insertion of a needle above the medial malleolus into the posterior tibial nerve followed by the application of low voltage (10mA, 1-10 Hz frequency) electrical stimulation, which produces sensory and motor responses (i.e., a tickling sensation and plantar flexion or fanning of all toes). Non-invasive PTNS has also been delivered with surface electrodes. The exact frequency and duration of PTNS therapy is not yet fully defined, though, most studies applied this therapy in 30-minute sessions given weekly for 12 weeks. The optimal interval for maintenance therapy is not yet established but is frequently performed every 3–4 weeks. Studies beyond 24 months have not been performed to identify benefit of continued treatment beyond 24 months.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health does not cover posterior tibial nerve stimulation (PTNS) when performed as first-line therapy for patients with overactive bladder (OAB). **Select Health may consider PTNS medically necessary** to treat patients with OAB and associated symptoms of urinary urgency, urinary frequency, and urge incontinence, when ALL the following criteria (1–4) have been met:

Covered Indications

1. Patient \geq age 18



Posterior Tibial Nerve Stimulation (PTNS), continued

2. The patient has experienced OAB with associated symptoms of urinary urgency, urinary frequency, and urge incontinence for at least 12 months, and the condition has resulted in significant disability [the symptoms are limiting the patient's ability to participate in activities of daily living (ADLs);] **and**
3. The patient has tried at least two different anti-cholinergic drugs, or a combination of an anti-cholinergic and a tricyclic drug for a period of four to six weeks without improvement, or the documentation shows the patient is unable to tolerate these types of drugs; **and**
4. The patient has tried behavioral treatments (e.g., pelvic floor exercise, biofeedback, timed voids, or fluid management (not an all-inclusive list), without improvement in the symptoms.

Treatment Limitations

5. PTNS standard treatment regimen (30-minute sessions given weekly for 12 weeks) will be covered for treatment of OAB symptoms for patients either refractory or intolerant to standard anti-cholinergic drug therapy (i.e., failed treatment with two anti-cholinergic drugs, each taken for at least 4 weeks duration, prior to the PTNS therapy initiation). If the patient fails to improve after 6 PTNS treatments, continued treatment is not considered medically necessary. Treatments beyond the initial 12 sessions will be allowed at a frequency of one treatment, every one to two months for the remainder of one year.
6. Another trial of the PTNS standard treatment regimen (30-minute sessions given weekly for 12 weeks) will be allowed for patients who have had successful treatment with PTNS and have returning symptoms of OAB after 24 months from the completion of the initial standard treatment regimen of PTNS.
7. PTNS treatment is contraindicated for patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function, or patients who are pregnant or planning to become pregnant during the duration of the treatment. Caution should be exercised for patients with heart problems related to pacing.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For this policy, specifically, there are no CMS criteria available; therefore, the Select Health Commercial policy or InterQual criteria apply. Select Health applies these requirements after careful review of the evidence that supports the clinical benefits outweigh the clinical risks. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Evidence has evolved since the PTNS was first approved in 2007. Hayes published an updated Directory Report on PTNS in 2015, with an additional update in 2016. Hayes now gives PTNS a 'B' rating for adults, with refractory OAB (non-neurogenic) and associated symptoms of urinary urgency, urinary frequency, and UUI. This rating is based on the large body of moderate-quality evidence that PTNS is superior to sham therapy, and at least as effective as active comparator treatments (e.g., antimuscarinic therapy, transvaginal electrical stimulation), with a treatment benefit that may persist for 12 to 36 months

Posterior Tibial Nerve Stimulation (PTNS), continued

with maintenance PTNS therapy. It continues to provide a 'D2' rating for adults with lower urinary tract disease (LUTD), secondary to multiple sclerosis (MS) or Parkinson's disease (PD), and for children with LUTD. In both latter instances, the rating is reflective of the small body of very-low-quality evidence demonstrating the efficacy of PTNS as treatment for LUTD.

From 2006 to 2010, only 10 papers met review standards for consideration. These papers evaluated over 500 patients. Since 2010, three systematic reviews and 12 primary studies were identified which met review standards. Results from 362 patients were reported in this cohort of primary literature articles. Notably, the quality of the studies had improved with new studies often being randomized and prospective, and comparative to other available therapies or sham treatment.

Important take-aways from the current literature regarding outcomes and methods include a lack of consensus regarding a standard treatment regimen, though, for the most part, efficacy of weekly treatments for 12 weeks followed by maintenance treatment every 3–4 weeks is the most common regimen employed. Currently the body of evidence has not illustrated a standardized, evidence-based maintenance protocol for these patients.

Regarding use of the PTNS technology in patients with Parkinson's disease or MS, current published evidence remains limited to 2 papers, with outcomes reported on 60 patients and little evidence for outcomes of patients with multiple sclerosis. Though suggestive of benefit, the evidence remains insufficient to reach conclusions regarding efficacy or safety of the therapy in these clinical settings.

In conclusion, evidence for efficacy and safety of PTNS for urinary incontinence in adults suggests some level of efficacy equivalent to currently available medications, though, the entire body of literature remains limited. The literature generally illustrates an improvement in OAB/UI symptoms at follow-up and there is now evidence of durability of effect out to 3 years follow-up time. There is discord among the articles regarding a standard treatment protocol for the treatment of these symptoms, but all regimens resulted in symptom reduction.

Billing/Coding Information

Covered for the indications listed above

CPT CODES

0816T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous
0817T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial
0818T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve;
0819T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

HCPCS CODES

No specific codes identified

Key References

1. Arrabal-Polo, MA, Palao-Yago, F, Campon-Pacheco, I, et al. (2012). Clinical efficacy in the treatment of overactive bladder refractory to anticholinergics by posterior tibial nerve stimulation. *Korean J Urol* 53.7: 483-6.
2. Blue Cross and Blue Shield Association. (2011). Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction. *Technol Eval Cent Assess Program Exec Summ* 25.8: 1-7.

Posterior Tibial Nerve Stimulation (PTNS), continued

3. Burton, C, Sajja, A, Latthe, PM. (2012). Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. *NeuroUrol Urodyn*.
4. Chen, HW, Bercik, RS, Werner, EF, et al. (2012). Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. *J Urol* 187.1: 178-84.
5. de Seze, M, Raibaut, P, Gallien, P, et al. (2011). Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. *NeuroUrol Urodyn* 30.3: 306-11.
6. Ferri, F.F. Incontinence, Urinary. 2017 [cited 2016 June 16]; Available from: <https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323280488004024>.
7. Finazzi-Agro, E., et al., Posterior tibial nerve stimulation: is the once-a-week protocol the best option? *Minerva Urol Nefrol*, 2005. 57(2): p. 119-23.
8. Finazzi-Agro, E, Petta, F, Sciobica, F, et al. (2010). Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol* 184.5: 2001-6.
9. Food and Drug Administration. (2011). FDA approves Botox to treat specific form of urinary incontinence. August 25, 2011.
10. Food and Drug Administration. Available: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269509.htm>. Date Accessed: September 17, 2012.
11. Gaziev, G., et al., Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. *BMC Urol*, 2013. 13: p. 61.
12. Gobbi, C, Digesu, GA, Khullar, V, et al. (2011). Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial. *Mult Scler* 17.12: 1514-9.
13. Hayes. Percutaneous Tibial Nerve Stimulation for the Treatment of Lower Urinary Tract Dysfunction. November 19, 2015 [cited 2016 June 17]; Available from: https://www.hayesinc.com/subscribers/displaySubscriberArticle.do?articleId=17376&searchStore=%24search_type%3Dall%24cd%3D%24keywords%3Dpercutaneous%2Ctibial%2Cnerve%2Cstimulation%24status%3Dall%24page%3D1%24from_date%3D%24to_date%3D%24report_type_options%3D%24technology_type_options%3D%24organ_system_options%3D%24specalty_options%3D%24order%3DsearchRelevance.
14. Hayes, Inc. Health Technology Assessment Percutaneous Tibial Nerve Stimulation for the Treatment of Symptomatic Neurogenic Lower Urinary Tract Dysfunction. April 1, 2022.
15. Hayes Medical Technology Directory. (2008). Electrical Percutaneous Tibial Nerve Stimulation for Urinary Voiding Dysfunction. Winifred S. Hayes Inc.
16. Kabay, S, Kabay, SC, Yucel, M, et al. (2009). The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. *NeuroUrol Urodyn* 28.8: 964-8.
17. Kabay, SC, Kabay, S, Yucel, M, et al. (2009). Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. *NeuroUrol Urodyn* 28.1: 62-7.
18. Kabay, SC, Yucel, M, Kabay, S. (2008). Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. *Urology* 71.4: 641-5.
19. Katz, VL. (2007). *Comprehensive Gynecology*. Philadelphia: Mosby Elsevier.
20. Kavoussi, LR. (2007). *Campbell-Walsh Urology*. Ed. Wein AJ. 9 ed. Philadelphia: Saunders Elsevier.
21. Levin, PJ, Wu, JM, Kawasaki, A, et al. (2012). The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. *Int Urogynecol J*.
22. MacDiarmid, SA, Peters, KM, Shobeiri, SA, et al. (2010). Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *J Urol* 183.1: 234-40.
23. Marchal, C, Herrera, B, Antuna, F, et al. (2011). Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started? *Urology* 78.5: 1046-50.
24. Mayo Clinic. (2010). Overactive Bladder. Last Update. Mayo Clinic. Available: <http://www.mayoclinic.com/health/overactive-bladder/DS00827>. Date Accessed: November 3, 2010.
25. Mayo Clinic. (2010). Urinary incontinence surgery: When other treatments aren't enough. Last Update. Mayo Clinic. Available: <http://www.mayoclinic.com/health/urinary-incontinence-surgery/WO00126>. Date Accessed: November 5, 2010.
26. Mayo Clinic. (2012). Urinary incontinence surgery: When other treatments aren't enough. Mayo Clinic. Available: <http://www.mayoclinic.com/health/urinary-incontinence-surgery/WO00126>. Date Accessed: September 7, 2012.
27. Monga, AK, Tracey, MR, Subbaroyan, J. (2012). A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. *Int Urogynecol J* 23.8: 993-1005.
28. Moosdorff-Steinhauser, HF, Berghmans, B. (2012). Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: A systematic review. *NeuroUrol Urodyn*.
29. Moosdorff-Steinhauser, H.F. and B. Berghmans, Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. *NeuroUrol Urodyn*, 2013. 32(3): p. 206-14.
30. National Institute for Health and Clinical Excellence. (2010) Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. October 2010. National Health Service Date Accessed: September 20, 2012.
31. National Institute for Health and Clinical Excellence. Urinary incontinence in women: management: Neurostimulation. 2015 November 2015 [cited 2016 June 17].
32. Peters, KM, Carrico, DJ, Macdiarmid, SA, et al. (2012). Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. *NeuroUrol Urodyn*.
33. Peters, K, Carrico, D, Burks, F. (2009). Validation of a sham for percutaneous tibial nerve stimulation (PTNS). *NeuroUrol Urodyn* 28.1: 58-61.
34. Peters, KM, Carrico, DJ, Perez-Marrero, RA, et al. (2010). Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUMiT trial. *J Urol* 183.4: 1438-43.
35. Peters, KM, Macdiarmid, SA, Wooldridge, LS, et al. (2009). Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol* 182.3: 1055-61.
36. Regence. (2010). Posterior Tibial Nerve Stimulation for Voiding Dysfunction. Last Update. Regence. Available: <http://blue.regence.com/trgmedpol/surgery/sur154.html>. Date Accessed: November 5, 2010.



SYNTHETIC BULKING AGENTS FOR STRESS URINARY CONTINENCE

Policy # 218

Implementation Date: 1/27/04

Review Dates: 1/13/05, 1/18/06, 2/16/06, 5/17/07, 6/19/08, 6/11/09, 6/17/10, 5/19/11, 6/21/12, 6/20/13, 4/17/14, 4/14/16, 4/27/17, 7/16/18, 4/17/19, 4/13/20, 4/15/21, 3/11/22, 5/1/23

Revision Dates: 4/17/20

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Periurethral bulking agents are substances that are injected into the submucosal tissues of the urethra and/or the bladder neck and into tissues adjacent to the urethra for the treatment of stress urinary incontinence resulting from intrinsic sphincter deficiency (ISD). Improvement in stress incontinence is achieved by increasing the tissue bulk and thereby increasing resistance to the outflow of urine. Cross-linked collagen (e.g., Contigen) has been commercially available for many years, but the use of carbon-coated beads (e.g., Durasphere) has also received approval by the U.S. Food and Drug Administration (FDA) as a periurethral bulking agent. The use of collagen is preceded by a skin test to rule out hypersensitivity. No such testing is required when carbon-coated beads are used. The substances may be injected over a course of several treatments until the desired effect is achieved. Since cross-linked collagen is slowly absorbed over time, symptoms may recur, requiring retreatment. The use of carbon-coated beads, Durasphere, is thought to provide a more durable effect. Periurethral bulking agents have been widely used for incontinence in women, and their FDA-labeled indication is limited to their use in women. However, men have also been treated, most commonly those with post-prostatectomy incontinence. Polytetrafluoroethylene (Teflon), silicone microimplants, autologous ear chondrocytes, and autologous fat are other implant materials that have been investigated. Their effectiveness has not yet been established in the medical literature.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers the Durasphere, Coaptite, and Macroplastique synthetic bulking agents for the treatment of stress urinary incontinence, as current evidence suggests that injection of these products is at least as effective as the currently covered implant procedure using collagen bulking agents (e.g., Contigen); and patient benefits, due to the more durable nature of the bulking agent, are expected to also be more durable.

Select Health does NOT cover other synthetic bulking agents for the treatment of stress urinary incontinence. These include, but are not limited to, polytetrafluoroethylene (Teflon), silicone microimplants, autologous ear chondrocytes, and autologous fat. These agents are considered investigational as their effectiveness and durability have not been established, especially when compared with other covered agents.

Synthetic Bulking Agents for Stress Urinary Incontinence, continued

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Neither Hayes, nor BCBS TEC, have produced reviews specific to the injection of synthetic bulking agents. However, there are several systematic reviews from the international body of literature, including 1 from Pickard et al., which stated: "... data from the available randomized trials suggest, but do not prove, that periurethral injection of established manufactured bulking agents results in subjective and objective short-term improvement of symptomatic female stress urinary incontinence in adults. Further, the 4 studies that compared different agents found that silicone particles and carbon spheres gave improvement at 12 months equivalent to collagen." Berman et al. further states that injection of collagen (demonstrated to be essentially equivalent to Durasphere) is substantially less effective than sling cystourethropepy.

There is only 1 controlled trial using carbon-coated beads (Durasphere). Lightner et al. reported that Durasphere for the treatment of stress urinary incontinence in women due to intrinsic sphincter deficiency was equally effective as bovine collagen and used less material (there was no placebo/sham control group in this trial).

"Data from the available randomized trials suggest, but do not prove, that periurethral injection of established manufactured bulking agents results in subjective and objective short-term improvement of symptomatic female stress urinary incontinence in adults. Future recommendation as a first line treatment would require evidence of patient benefit and cost-effectiveness from randomized trials involving placebo and conservative treatment arms. Future studies should also record long-term outcome and monitor for delayed particle migration. Injection therapy is probably inferior to surgery but a long-term comparative study against a single standard procedure (Burch colposuspension) is required to prove this. It is recommended that phase III studies of newer agents will not be worthwhile until the aforementioned trials have been performed and a rationale for the use of injection therapy decided. For women with extensive co-morbidity precluding anesthesia, injection therapy may represent a useful option for relief of symptoms for a 12-month period although 2–3 injections are likely to be required to achieve a satisfactory result."

Other trials on bovine collagen (i.e., Contigen) report good short-term benefits with few complications but poor mid- to long-term outcomes especially regarding durability.

Billing/Coding Information

Covered: For the conditions listed above

CPT CODES

- | | |
|-------|---|
| 51715 | Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck |
| 52327 | Cystourethroscopy (including ureteral catheterization); with subureteric injection of implant material |

Synthetic Bulking Agents for Stress Urinary Incontinence, continued

HCPCS CODES

- L8603** Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessary supplies
- L8604** Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies
- L8606** Injectable bulking agent synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies

Key References

1. Cochrane review: Pickard R, Reaper J, Wyness L, Cody DJ, McClinton S, N'Dow J. Periurethral injection therapy for urinary incontinence in women (Cochrane Review). In: The Cochrane Library, A substantive amendment to this systematic review was last made on 24 2/2003. Chichester, UK.
2. Corcos J, Fournier C. Periurethral collagen injection for the treatment of female stress urinary incontinence: 4-year follow-up results. *Urology*. 1999 Nov;54(5):815-8. PMID: 10565739
3. Gorton E, Stanton S, Monga A, Wiskind AK, Lentz GM, Bland DR. Periurethral collagen injection: a long-term follow-up study. *BJU Int*. 1999 Dec;84(9):966-71. PMID: 10571621
4. Herschom S. Current status of injectable agents for female stress urinary incontinence. *Can J Urol*. 2001 Jun;8(3):1281-9. Review. PMID: 11423016
5. Kershen RT, Dmochowski RR, Appell RA. Beyond collagen: injectable therapies for the treatment of female stress urinary incontinence in the new millennium. *Urol Clin North Am*. 2002 Aug;29(3):559-74. Review. PMID: 12476520
6. Klutke JJ, Subir C, Andriole G, Klutke CG. Long-term results after antegrade collagen injection for stress urinary incontinence following radical retropubic prostatectomy. *Urology*. 1999 May; 53(5):974-7. PMID: 10223492
7. Lightner DJ, Itano NB, Sweat SD, Chrouser KL, Fick F. Injectable agents: present and future. *Curr Urol Rep*. 2002 Oct;3(5):408-13. Review. PMID: 12354352
8. Lightner DJ. Review of the available urethral bulking agents. *Curr Opin Urol*. 2002 Jul;12(4):333-8. Review. PMID: 12072655
9. Lightner D, Calvosa C, Andersen R, Klimberg I, Brito CG, Snyder J, Gleason D, Killion D, Macdonald J, Khan AU, Diokno A, Sirls LT, Saltzstein D. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. *Urology*. 2001 Jul;58(1):12-5. PMID: 11445471
10. Meschia M, Pifarotti P, Gattei U, Crosignani PG. Injection therapy for the treatment of stress urinary incontinence in women. *Gynecol Obstet Invest*. 2002;54(2):67-72. Review. PMID: 12566746

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



TRANSURETHRAL LASER VAPORIZATION (TLV) PROSTATECTOMY FOR BENIGN PROSTATIC HYPERTROPHY (BPH)

Policy # 229

Implementation Date: 5/15/04

Review Dates: 4/14/05, 5/5/06, 12/21/06, 12/20/07, 12/18/08, 4/23/09, 4/22/10, 8/16/11, 8/16/12, 8/15/13, 6/19/14, 6/11/15, 6/16/16, 6/15/17, 7/16/18, 6/20/19, 6/18/20, 6/17/21, 5/19/22, 6/15/23

Revision Dates:

Related Medical Policies:

[#182 Transurethral Needle Ablation \(TUNA\)](#)

[#183 Transurethral Microwave Therapy \(TUMT\)](#)

[#553 Urolift System for the Treatment of Benign Prostatic Hyperplasia](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

In general, laser energy can be used to produce coagulation necrosis, vaporization of tissue, or resection of tissue; such procedures are commonly referred to as transurethral laser coagulation, transurethral laser vaporization, and transurethral holmium laser resection/ enucleation, respectively. Initial experiences with bare laser fibers using neodymium: yttrium-aluminum-garnet (Nd:YAG) laser technology have been disappointing, primarily because of their inability to penetrate deeply into the tissue. Investigators do not agree on the optimal technique of energy delivery. Some of the laser technologies produce coagulation necrosis with delayed slough of tissue. Other lasers result in immediate tissue vaporization and ablation.

Transurethral laser vaporization (TLV) is a technique where the prostate tissue is vaporized using laser energy. The laser fiber is maintained in contact (in contrast to the coagulation procedure during which the fiber is kept at a distance from the tissue) with the area to be treated (a "contact" technique) and a series of furrows is made until a wide channel is obtained. Any patient with an obstructive prostate, who fails medical therapy, or fails other forms of therapy, such as transurethral needle ablation or microwave therapy, would be a candidate for laser TLV. There is a prostate size limit of 120 cc for TLV, which is pretty much the limit for transurethral resection (TURP). When the prostate reaches 90–100 cc, urologists will usually perform "open" enucleation rather than TURP. Prostates as large as 120 cc volume, however, can be treated with TLV.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health covers transurethral laser vaporization (TLV) prostatectomy for benign prostatic hypertrophy (BPH). This technology has been shown to be as safe and effective as other methods of prostate surgery currently approved by Select Health.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage,



Transurethral Laser Vaporization (TLV) Prostatectomy for Benign Prostatic Hypertrophy (BPH), continued

please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Although the available data on the effectiveness of laser therapies for the treatment of BPH are not definitive, especially so for the “emerging” high power potassium-titanyl-phosphate (KTP) laser device, it is clear from the literature, that these devices offer significant benefits for many patients with moderate-to-severe BPH, when applied by an experienced urologic surgeon. All options available for these patients are in a constant state of advancement, particularly the surgical therapies, as the tools for removing excessive prostatic tissue continue to become more efficient with less morbidity.

Laser vaporization of the prostate results in equivalent short-term improvements in symptom scores, urinary flow rate, and quality-of-life indices when compared to TURP. In addition, the rates of postoperative urinary retention and the need for unplanned secondary catheterization reported with laser vaporization also appear to be higher than for TURP.

Data suggests the intermediate-term, symptomatic improvement obtained after holmium laser resection may be comparable to that obtained after TURP, with a slightly reduced risk of bleeding and need for blood transfusions and an absence of TURP syndrome.

Early studies of a 60W high power KTP laser in living canine and human cadaveric prostates showed effectiveness in creating large cavities. Preliminary results of clinical experience with the high power KTP laser (60W) as a vaporizing modality have been published by Carter et al. They treated 22 consecutive patients using Addstat (Laserscope) side-fire laser delivery. Sixteen patients had their catheters removed on day one and only 1 failed a trial of void while the remaining 6 patients were left without a catheter and all voided freely post-operatively. Mean peak flow rates improved from 10 mL/s to 22.4 mL/s and mean IPSS decreased from 17.3 to 9.6 at 6 weeks of follow-up.

Transurethral laser coagulation of the prostate is an effective surgical treatment for men with BPH. Although improvements in symptom scores, quality-of-life indices, and flow rate, are equivalent to those attained after TURP, significantly higher rates of unplanned, prolonged, postoperative urinary catheterization and a higher incidence of post-procedure irritative voiding symptoms are reported. The American Urology Association (AUA) panel's meta-analysis found that the rate of acute urinary retention requiring secondary catheterization post-transurethral laser coagulation was 21% in the single-arm analysis, significantly higher than that observed post-TURP (5%, single-arm analysis only). The rate of post-procedure irritative voiding symptoms observed after transurethral laser coagulation in the meta-analysis of two randomized, direct comparison trials was not significantly different from the rate (15%) observed after TURP. However, the single-arm rate of irritative voiding symptoms after laser coagulation (66%) appears significantly higher than the 15% rate observed after TURP. The reason for this variation is not clear.

Billing/Coding Information

CPT CODES

52648 Laser vaporization of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, internal urethrotomy and transurethral resection of prostate are included if performed)

HCPCS CODES

C1726 Catheter, balloon dilatation, non-vascular

Transurethral Laser Vaporization (TLV) Prostatectomy for Benign Prostatic Hypertrophy (BPH), continued

C1758	Catheter, ureteral
C1769	Guide wire
C1782	Morcellator
C2627	Catheter, suprapubic/cystoscopic

Key References

1. Aho TF, Gilling PJ. Laser therapy for benign prostatic hyperplasia: a review of recent developments. *Curr Opin Urol*. 2003 Jan;13(1):39-44.
2. American Urological Association Guideline on Management of BPH (8/2003). Chapter 1: Diagnosis & Treatment Recommendations
3. Australian Safety and Efficacy Register of New Interventional Procedures – Surgical: Holmium Laser Prostatectomy for Benign Prostatic Hyperplasia. 6/2003.
4. Bachmann, S. Wyler, R. Ruszat, Th. Gasser, T. Sulser. Photoselective KTP Laser Vaporisation of the Prostate. First Experiences After 50 Procedures. *J. Endourol*. Vol. 17, Suppl. 1, 9/2003, p. A188.
5. Carter A, Sells H, Speakman M, Ewings P, O'Boyle P, MacDonagh R. Quality of life changes following KTP/Nd:YAG laser treatment of the prostate and TURP. *Eur Urol*. 1999 Aug;36(2):92-8.
6. Chahal R, Sundaram SK, Gogoi NK. Assessment of voiding outcome, sexual function and quality of life two years following KTP/YAG hybrid laser prostatectomy. *Urol Int*. 2000;65(3):125-9.
7. Hai MA, Malek RS. Photoselective vaporization of the prostate: initial experience with a new 80 W KTP laser for the treatment of benign prostatic hyperplasia. *J Endourol*. 2003 Mar;17(2):93-6.
8. Hayes Report – Laser Prostatectomy For Benign Prostatic Hyperplasia, 6/2002.
9. Kuntzman RS, Malek RS, Barrett DM. High-power potassium titanyl phosphate laser vaporization prostatectomy. *Mayo Clin Proc*. 1998 Aug;73(8):798-801.
10. Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. *J Urol*. 2000 Jun;163(6):1730-3.
11. Mattioli, S., Cremona, M., Pozzoni, F.. Photoselective Laser Vaporization Of The Prostate (Pvp) For Treatment Of Benign Prostatic Hyperplasia (BPH). *J. Endourol*. Vol. 17, Suppl. 1, 9/2003, p. A318.
12. Nagahama K, Tamaki M, Takahashi T, Sanada S. [Clinical outcome of potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy for benign prostate hyperplasia]. *Nippon Hinyokika Gakkai Zasshi*. 2001 May;92(4):498-505.
13. Sandhu, J.S., VanderBrink, B.A., Egan, C., Kaplan, S.A., Te, A.E. High-Power KTP Photoselective Laser Vaporization Prostatectomy for the Treatment of Benign Prostatic Hyperplasia in Men with Large Prostates. *J. Endourol*. Vol. 17, Suppl. 1, 9/2003, p. A188.
14. Shingleton WB, Terrell F, Renfro DL, Kolski JM, Fowler JE Jr. A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia. *Urology*. 1999 Dec;54(6):1017-21.
15. Ulchaker, J.C., Malloy, T.R., Stein, B., Te, A.E., Nseyo, U.O., Hai, M.A., Malek, R.S. Photoselective Vaporization of the Prostate (PVP) or Treatment of Benign Prostatic Hyperplasia (BPH): A Prospective Multi-Center Trial. *J. Endourol*. Vol. 17, Suppl. 1, 9/2003, p. A319
16. Ulchaker, J.C., Te, A.E., Egan, C., Sandhu, J.S., Nseyo, U. O. Photoselective Vaporization of the Prostate (PVP) for Treatment of Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH). *J. Endourol*. Vol. 17, Suppl. 1, 9/2003, p. A187.
17. "A Clinical Outcomes & Economic Cost Analysis Comparing Photoselective Vaporization of the Prostate to Alternative Minimally Invasive Therapies & TURP for the Treatment of Benign Prostatic Hyperplasia". (Mark D. Stovsky, MD, MBA*, Robert I. Griffiths, MS, Sc.D., Carol R. Laskin BA MRP).
18. "High-power KTP Photoselective Laser Vaporization Prostatectomy for the Treatment of Benign Prostatic Hyperplasia in men with large prostates". (Jaspreet S. Sandhu*, Brian A. VanderBrink, Celeste Egan, Steven A. Kaplan, and Alexis E. Te)
19. "High-power KTP photoselective laser vaporization prostatectomy (PVP) versus transurethral electrovaporization of the prostate (TVP) for the treatment of benign prostatic hyperplasia (BPH): A Prospective Comparative Trial". (Alexis E Te*, Jaspreet S Sandhu, Ricardo R Gonzalez, Celeste Egan, Steven A Kaplan, New York).
20. "Photoselective Vaporization of the Prostate (PVP) for the Treatment of Benign Prostatic Hyperplasia (BPH): 12-month results from the first U.S. Multi-Center Prospective Trial". (Alexis E. Te*, Terrence R. Malloy, Barry S. Stein, James C. Ulchaker, Unyime O. Nseyo, Mahmood A. Hai & Reza S. Malek)
21. "Photoselective Vaporization of the Prostate (PVP) for the Treatment of Benign Prostatic Hyperplasia: a 3-year Experience". (Mahmood A. Hai* and Muzammil M. Ahmed, Wayne, MI)
22. "Photoselective Vaporization of the Prostate (PVP) for the Treatment of Benign Prostatic Hyperplasia (BPH): 2-year results from the first U.S. Multi-Center Prospective Trial". (Alexis E. Te, Terrence R. Malloy, Barry S. Stein, James C. Ulchaker, Unyime O. Nseyo, Mahmood A. Hai & Reza S. Malek)
23. "Photoselective Vaporization of the: 5-year Experience with High-Power KTP laser." (R.S. Malek, Rochester, R.S. Kuntzman, Grand Rapids, MI), *Canadian Urological Association*, 6/27 - 7/1/04.
24. "80W high-power KTP laser vaporization of the prostate. Clinical results after 110 consecutive procedures". (A. Bachmann et al.)

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

Genitourinary Policies, Continued

Transurethral Laser Vaporization (TLV) Prostatectomy for Benign Prostatic Hypertrophy (BPH), continued

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health[®] makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



TRANSURETHRAL RADIOFREQUENCY (RF) FOR STRESS URINARY INCONTINENCE (SUI) (E.G., RENESSA)

Policy # 352

Implementation Date: 5/12/07

Review Dates: 4/24/08, 4/23/09, 6/21/12, 11/29/12, 6/20/13, 4/17/14, 4/14/16, 4/27/17, 7/16/18, 4/17/19, 4/13/20, 4/15/21, 3/11/22, 5/1/23

Revision Dates: 5/6/11

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Urinary incontinence is loss of bladder control. Symptoms can range from mild leaking to uncontrollable wetting. It can happen to anyone, but it becomes more common with age. Stress urinary incontinence (SUI) is the most common cause of urinary incontinence in younger women and the second most common cause in older women. Stress leakage occurs when increases in intra-abdominal pressure overcome sphincter closure mechanisms in the absence of a bladder contraction. Stress incontinence often coexists with urge incontinence in middle-aged and older women. This is considered "mixed" incontinence. The prevalence of specific types of incontinence is difficult to estimate because of wide variation in definitions. In general, about half of affected women have stress incontinence, with mixed stress and urge next common, and urge incontinence least common.

Surgery is the most effective treatment and may be an option for women who fail more conservative therapies. A minimally invasive alternative to surgical procedures involves using radiofrequency (RF) to generate controlled heat at low temperatures in tissue targets within the lower urinary tract. The Renessa System (Novasys Medical, Inc) is a transurethral procedure that uses RF energy to generate heat to denature collagen in the tissue at multiple small treatment sites but is low enough to prevent gross tissue destruction. Upon healing, the treated tissue is firmer, increasing resistance to involuntary leakage at times of heightened intra-abdominal pressure, such as laughing, coughing, or during exercise, thereby reducing or eliminating SUI episodes.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does NOT cover transurethral radiofrequency (RF) for stress urinary incontinence (SUI) (e.g., Renessa). Current evidence demonstrates inferior efficacy and durability to other standard approaches; this meets the plan's definition of not medically necessary.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)



Transurethral Radiofrequency (RF) for Stress Urinary Incontinence (SUI) [e.g., Renessa®], continued

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The literature identified on this technology was limited to reviews of 6 empiric studies. A Hayes 2007 Health Technology Brief noted that the limited literature suggests some efficacy among patients with severe SUI, but conclusions are tempered by a lack of blinded assessment, long-term follow-up, comparisons to alternatives, and a high rate of placebo responses. The Australia and New Zealand Horizon Scanning Network also noted the potential benefits of the Renessa system but concluded that long-term safety and efficacy must be established before coverage could be recommended.

Our review of the literature yielded similar conclusions. The literature offers 2 pilot studies and 1 manufacturer-sponsored randomized controlled trial with limited follow-up. In Appel et al., 173 women with SUI were treated with RF or a sham procedure. Treatment outcomes were incontinence quality of life (IQoL) and leak point pressure (LPP). The incidence of adverse events was similar between groups. At 12 months, there was no difference in the percentage of RF and sham recipients who achieved a ≥ 10 -point improvement in self-reported IQoL (48% vs. 44%, respectively). In moderate-to-severe SUI patients, 74% of RF patients achieved a ≥ 10 -point improvement in IQoL compared to 50% of sham patients. This RF subgroup also had a mean increase in LPP of 13.2 ± 39.2 cm H₂O compared to a mean decrease of 2.0 ± 33.8 cm H₂O. Two additional studies reported 6 and 12-month follow-up outcomes in 41 patients with SUI who underwent the Renessa procedure. At 6 months, 75%–80% of patients had experienced a ≥ 10 -point improvement in self-reported IQoL, a rate maintained at the 12-month follow-up. Neither of these studies reported any statistical analyses of these results, and without an appropriate control group, conclusions about these results are limited.

Typically, a single randomized controlled trial is insufficient to establish the efficacy of a treatment. In this case, the large placebo effect in the sham treatment group, lack of blinded outcomes measurement, limited long-term follow-up, and manufacturer sponsorship weaken any conclusions that could be made from these results. Additional randomized controlled trials that include surgical comparators are needed before the efficacy of transvaginal radiofrequency is established as legitimate treatment for SUI.

A Medical Technology Assessment performed in May 2011 identified 4 systematic reviews and 3 peer-reviewed journal articles regarding transurethral radiotherapy for the treatment of urinary incontinence published since the previous review in 2007.

In March 2010, Hayes published a brief on this particular technology and reported: "This therapy can be performed safely and relatively painlessly using local anesthesia and an oral sedative and may be an option for patients who cannot tolerate conscious sedation or anesthesia. Despite these positive findings, the strength of the existing data is somewhat weakened by flaws in study design and execution, particularly the loss of high numbers of patients to follow up and the lack of controls in some studies. Although no serious adverse events were reported, minor complications occurred such as dysuria, urinary retention and urinary tract infection. Additional independent studies are required to establish the long-term safety and efficacy of this technology since the manufacturer sponsored the existing studies. Nevertheless, RF energy-therapy might be an appropriate option for patients who are not eligible for or who wish to avoid invasive surgery."

The Australia and New Zealand Horizon Scanning Network (ABZHSN) completed in 2007 reached similar conclusions, noting that although no serious adverse events were reported in any of the studies reviewed, further long-term studies be completed to establish the long-term safety and efficacy of the device and procedure.

Contrary to these findings, in 2008, the California Technology Assessment Forum (CTAF) found that Renessa met all 5 of their criteria for safety, effectiveness, and improvement in health outcomes for the

Transurethral Radiofrequency (RF) for Stress Urinary Incontinence (SUI) [e.g., Renessa®], continued

treatment of moderate-to-severe female stress urinary incontinence in non-pregnant women, who are either not able, or who are not willing to undergo surgery for their SUI treatment.

Supporting the CTAF review, Appell et al., and Elser et al., both concluded durability of the procedure out to 3 years to be present. However, they defined durability of the effect to be at least a 50% reduction in urinary frequency. It was notable that in the Appell study this was achieved in only 56% of patients and only 50% in the Elser study. Though the systematic reviews and peer-reviewed literature conclude that radiofrequency ablation in this setting is safe, it is evident that the procedure is not as effective as current treatments in decreasing voiding frequency to a statistically significant degree.

Billing/Coding Information

Not covered: Investigational/Experimental/Unproven for this indication

CPT CODES

53860 Transurethral radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence

HCPCS CODES

No specific codes identified

Key References

1. Appell RA, Juma S, Wells WG, et al. (2006). Transurethral radiofrequency energy collagen micro-remodeling for the treatment of female stress urinary incontinence. *Neurourol Urodyn* 25.4: 331-6.
2. Appell, RA, Singh, G, Klimberg, IW, et al. (2007). Nonsurgical, radiofrequency collagen denaturation for stress urinary incontinence: retrospective 3-year evaluation. *Expert Rev Med Devices* 4.4: 455-61.
3. Australia and New Zealand Horizon Scanning Network. (2006) Horizon Scanning Technology Prioritising Summaries: Renessa® radiofrequency micro-remodelling treatment for female stress urinary incontinence. Health Policy Advisory Committee on Technology (Australia and New Zealand). Available: [http://www.health.gov.au/internet/horizon/publishing.nsf/Content/2E6BEDBA8F538999CA25714E00200B64/\\$File/Renessa%20System%20treatment%20Sept2006.pdf](http://www.health.gov.au/internet/horizon/publishing.nsf/Content/2E6BEDBA8F538999CA25714E00200B64/$File/Renessa%20System%20treatment%20Sept2006.pdf). Date Accessed: March 7, 2007.
4. Culligan, P.J. (2007). *Urogynecology in Primary Care*. London: Springer-Verlag.
5. Doughty, DB. (2006). *Urinary & Fecal Incontinence, Current Management Concepts*. Elsevier.
6. DuBeau CE. (2006). Clinical presentation and diagnosis of urinary incontinence. UpToDate. Available: http://www.uptodate.com/utd/content/topic.do?topicKey=pc_neph/2274&type=A&selectedTitle=3~11. Date Accessed: March 6, 2007.
7. DuBeau, CE. (2011) Epidemiology, risk factors, and pathogenesis of urinary incontinence. Last Update: September 13, 2010. Up to Date. Available: <http://www.uptodate.com/contents/epidemiology-risk-factors-and-pathogenesis-of-urinary-incontinence?source=HISTORY>. Date Accessed: April 25, 2011.
8. DuBeau, CE. (2011) Treatment of urinary incontinence. Last Update: January 30, 2011. Up to Date. Available: http://www.uptodate.com/contents/treatment-of-urinary-incontinence?source=related_link. Date Accessed: April 25, 2011.
9. Dzurinko, MK. (1997). *The Urinary Incontinence Sourcebook*. McGraw-Hill Professional.
10. Elser, DM, Mitchell, GK, Miklos, JR, et al. (2009). Nonsurgical transurethral collagen denaturation for stress urinary incontinence in women: 12-month results from a prospective long-term study. *J Minim Invasive Gynecol* 16.1: 56-62.
11. Food and Drug Administration (FDA). (2005) 501(k) Premarket Notification: Novasys Medical's Transurethral RF System. Last Update: July 22, 2005. U.S. Department of Health & Human Services. Available: http://www.accessdata.fda.gov/cdrh_docs/pdf4/K042132.pdf. Date Accessed: March 24, 2011.
12. Hayes Brief - Technology at a Glance. (2010) Transurethral Radiofrequency Micro-Remodeling Using the Renessa® System (Novasys Medical Inc.) for Female Stress Urinary Incontinence. Winifred S. Hayes Inc.
13. Health Technology Brief. (2007) Transurethral Radiofrequency Micro-Remodeling Using the Renessa® System (Novasys Medical Inc.) for Female Stress Urinary Incontinence. Winifred S. Hayes, Inc. Available: <https://www.hayesinc.com/subscribers/displaySubscriberArticle.do?articleId=5603&targetList=searchArticles.do&query=incontinence&icdQuery=&sd1=searchRelevance&sd2=transformdatesort&sd3=transformdoctype&sd4=transformsort>. Date Accessed: March 6, 2007.
14. Juma, S, Appell, RA. (2007). Nonsurgical transurethral radiofrequency treatment of stress urinary incontinence in women. *Womens Health (Lond Engl)* 3.3: 291-9.
15. Karliner, L. (2008) Radiofrequency Micro-remodeling for the Treatment of Female Stress Urinary Incontinence. California Technology Assessment Forum (CTAF).
16. Khan F, Flesh G. (2006). Surgical treatment of stress urinary incontinence in women. UpToDate. Available: http://www.uptodate.com/utd/content/topic.do?topicKey=gen_gyne/7640. Date Accessed: March 6, 2007.
17. Mayo Clinic Staff. (2009) Urinary Incontinence: Symptoms. Last Update: June 27, 2009. Mayo Foundation for Medical Education and Research (MFMER). Available: <http://www.mayoclinic.com/health/urinary-incontinence/DS00404/DSECTION=symptoms>. Date Accessed: April 6, 2011.
18. MedlinePlus. (2011) Urinary Incontinence. Last Update: April 7, 2011. U.S. National Library of Medicine National Institutes of Health. Available: <http://www.nlm.nih.gov/medlineplus/urinaryincontinence.html>. Date Accessed: April 6, 2011.

Transurethral Radiofrequency (RF) for Stress Urinary Incontinence (SUI) [e.g., Renessa®], continued

19. National Association for Continence. (2011) Urinary Incontinence: Prevalence. Last Update: July 1, 2009. National Association for Continence (NAFC). Available: <http://www.nafc.org/media/statistics/prevalence-2/>. Date Accessed: April 6, 2011.
20. Novasys Medical. (2007). Available: <http://www.novasysmedical.com/aboutus.html>. Date Accessed: March 6, 2007.
21. Rackley R, Vasavada SP. (2006). Incontinence, Urinary: Nonsurgical Therapies. E-Medicine Website. Available: <http://www.emedicine.com/med/topic3085.htm#section-clinical>. Date Accessed: March 6, 2007.
22. Rackley R, Vasavada SP. (2006). Incontinence, Urinary: Surgical Therapies. E-Medicine. Available: <http://www.emedicine.com/med/topic3084.htm>. Date Accessed: March 6, 2007.
23. Sotomayor M, Bernal GF. (2003). Transurethral delivery of radiofrequency energy for tissue micro-remodeling in the treatment of stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*, 14.6: 373-9.
24. Sotomayor M, Bernal GF. (2005). Twelve-month results of nonsurgical radiofrequency energy micro-remodeling for stress incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*, 16.3: 192-6; discussion 196.
25. White, L. (2005). Foundations of Nursing.
26. Zamonra, L. (2007) Emerging Technology Bulletin: Renessa® radiofrequency micro-remodelling treatment for female stress urinary incontinence. Australia and New Zealand Horizon Scanning Network (ANZHSN).

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



PROSTATIC URETHRAL LIFT (UROLIFT) FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Policy # 553

Implementation Date: 7/29/14

Review Dates: 8/20/15, 8/25/16, 8/17/17, 7/16/18, 6/20/19, 2/10/20, 6/17/21, 5/19/22, 6/15/23

Revision Dates: 1/1/15, 3/22/16, 4/22/16, 12/5/18, 2/27/20, 10/19/20, 2/16/22, 6/1/22

Related Medical Policies:

[#229 Transurethral Laser Vaporization \(TLV\) Prostatectomy for Benign Prostatic Hypertrophy \(BPH\)](#)

[#182 Transurethral Needle Ablation \(TUNA\)](#)

[#183 Transurethral Microwave Therapy \(TUMT\)](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Benign prostatic hyperplasia (BPH) is the nonmalignant proliferation of the epithelial and stromal cells of the prostate gland. It is a gradually progressive histologic change that leads to the enlargement of the prostate, primarily in older men. BPH may or may not be symptomatic. When BPH produces symptoms, it is termed BPH-lower urinary tract symptoms (BPH-LUTS) or clinical BPH.

The prevalence of histologic BPH is estimated at 90% among men in the eighth decade of life. The prevalence of clinical BPH is approximately 50% in the same age group. Advanced age, obesity, increased fat intake, decreased physical activity, and diabetes, increase the risk of BPH development.

BPH is diagnosed based on the clinical history, digital rectal examination (DRE) findings, and focused urologic examination findings. Urinalysis is the only laboratory test universally recommended for BPH. Serum prostate-specific antigen (PSA) levels can be used as a marker for prostatic diseases, including BPH.

The decision to treat is usually based on the severity of symptoms and the patient's tolerance for these symptoms. Symptoms only require therapy if they have a significant impact on a patient's quality of life. Even without therapy, many men will experience stabilization or improvement in symptoms over time. Surgical and medical therapy is used to treat BPH, with surgery usually reserved only for patients who have failed conservative medical therapy, are intolerant to the medications, or have persisting symptoms/evidence for clinically significant persisting lower urinary obstruction despite maximal medical therapy. Alpha-1-adrenergic antagonists, 5-alpha-reductase inhibitors, and PDE-5 inhibitors represent the majority of medicinal treatments for BPH. Surgical interventions are typically employed only after failure or intolerance of conservative therapy or if the patient has obstructive symptoms requiring more immediate intervention. Transurethral resection of the prostate (TURP), laser prostatectomy, transurethral incision of the prostate, electrovaporization, open prostatectomy, transurethral needle ablation of the prostate (TUNA), transurethral microwave thermotherapy (TUMT), urethral stents, and botulinum toxin (this therapy is not FDA approved in the US and is not widely used in routine practice in the US) represent surgical options for BPH.

The UroLift System (NeoTract, Inc., Pleasanton, CA) is a minimally invasive approach to treating BPH that holds the enlarged prostate tissue out of the way, so it no longer blocks the urethra. There is no cutting, heating, or removal of prostate tissue. This minimally invasive procedure is routinely done under local anesthesia in the office or outpatient setting. The delivery system is used by the physician to mechanically open the prostatic urethra by placing permanent implants across the lobes of the prostate to



Urolift System® for the Treatment of Benign Prostatic Hyperplasia, continued

separate the encroaching prostatic lobes. Every implant is assembled and tailored *in situ* as it is delivered, based on the unique prostatic lobe characteristics. The transprostatic implants hold the prostatic urethra in a less obstructed configuration, thereby mitigating BPH symptoms. Each delivery device deploys one implant, and a typical procedure requires 4 implants (manufacturer reports since launch put the average number of implants used per procedure at 4.9), while most of the literature to date states mean slightly < 4 clips were used with a range of 2–7.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers prostatic urethral lift (UroLift) for the treatment of benign prostatic hyperplasia when the following criteria are met:

1. For men \geq 45 years of age with prostate volumes less than 100 cc; and
2. Failure of \geq 3 months of conservative therapy, which would include failed treatment with both an alpha-1-adrenergic antagonist and a 5-alpha-reductase inhibitor, or intolerance of BPH medications, or medical therapy is contraindicated in the member.

Select Health will cover a maximum of 7 prostatic urethral lift implants for the procedure. If more than 7 implants are recommended, then clinical documentation to justify medical necessity is required.

If a second prostatic urethral lift procedure is requested, an explanation of why other prostatic removal procedures are not clinically indicated, is required.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For this policy, specifically, there are no CMS criteria available; therefore, the Select Health Commercial policy or InterQual criteria apply. Select Health applies these requirements after careful review of the evidence that supports the clinical benefits outweigh the clinical risks. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Studies of urethral lift devices so far have lacked comparison to alternative available technologies to treat BPH. A review by NICE published in 2014, stated: "Current evidence on the efficacy and safety of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent, and audit." However, a 2019 update from NICE recommended UroLift as follows:

Urolift System® for the Treatment of Benign Prostatic Hyperplasia, continued

- The clinical case for adopting the UroLift system for treating lower urinary tract symptoms of benign prostatic hyperplasia is supported by the evidence. The UroLift system relieves lower urinary tract symptoms while avoiding the risk to sexual function associated with TURP and holmium laser enucleation of the prostate (HoLEP). Using the system reduces the length of a person's stay in hospital. It can also be used in a day-surgery unit.
- The UroLift system should be considered as an alternative to current surgical procedures for use in a day-case setting in men with lower urinary tract symptoms of benign prostatic hyperplasia who are aged 50 years and older and who have a prostate of less than 100 ml without an obstructing middle lobe.

Roehrborn et al. have two studies in print extending past 2 years. There is data from 19 centers in North America and Australia for 206 patients (randomized 140 to UroLift, 66 to control [sham]). 15 patients (10.7%) required revisions up to the 3-year follow-up and 13.6% required revisions at 5 years. Statistically significant improvements in International Prostate Symptom Scores (IPSS), peak flow-rate (Qmax), male sexual health questionnaire for ejaculatory dysfunction (MSHQ-EJD), and quality of life (QoL) scores were demonstrated; however, approximately one-third of the initial study patients experienced unsatisfactory results at 5 years.

Concerns regarding the lack of comparison of UroLift to standard treatment options, not just sham, were addressed in a 2015 prospective, randomized, controlled, multi-centered trial by Sonksen et al. of 80 men followed for 1 year, in which UroLift was compared to TURP. The study concluded that statistically significant superiority was illustrated with use of UroLift than with TURP in preservation of ejaculation function, symptom relief, and QoL. Overall, current published evidence supports safety and efficacy of UroLift implants out to 5 years, likely resulting in similar outcomes to alternatively available treatments.

Billing/Coding Information

CPT CODES

- 52441** Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
- 52442** Cystourethroscopy, with insertion of permanent adjustable transprostatic implant, each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)

HCPCS CODES

- C9739** Cystourethroscopy with insertion of transprostatic implant 1 to 3 implants
- C9740** Cystourethroscopy with insertion of transprostatic implant; 4 or more implants
- C9769** Cystourethroscopy, with insertion of temporary prostatic implant/stent with fixation/anchor and incisional struts

Key References

1. Beurrier, S., et al., [Are the UroLift((R)) implants an alternative for the treatment of benign prostatic hyperplasia? Short-term results and predictive factors of failure]. *Prog Urol*, 2015. 25(9): p. 523-9.
2. Boyle, P., et al., Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. *Urology*, 2000. 55(4): p. 533-9.
3. Bozkurt, A., et al., Prostatic Urethral Lift: A New Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Urol Int*, 2015.
4. Cantwell, A.L., et al., Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *BJU International*, 2014. 113(4): p. 615-622.
5. Chapple, C.R., Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. *BJU Int*, 2004. 94(5): p. 738-44.
6. Chin, P.T., et al., Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*, 2012. 79(1): p. 5-11.
7. Cunningham, C.R. Surgical and other invasive therapies of benign prostatic hyperplasia. accessed January 21, 2020. Available from: http://www.uptodate.com/contents/surgical-and-other-invasive-therapies-of-benign-prostatic-hyperplasia?source=search_result&search=bph&selectedTitle=4~150.
8. Cunningham, G.R. Medical treatment of benign prostatic hyperplasia. accessed Jan 21, 2010 Available from: <http://www.uptodate.com/contents/medical-treatment-of-benign-prostatic-hyperplasia?source=preview&language=en-US&anchor=H20#H20>.

Urolift System® for the Treatment of Benign Prostatic Hyperplasia, continued

9. Das AK, Leong JY, Roehrborn CG. Office-based therapies for benign prostatic hyperplasia: a review and update. *Can J Urol*, 2019. 26(Suppl 1): 2-7.
10. Foster HE, MD; Barry, MJ, Gandhi MC, et al. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019). [https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-\(bph\)-guideline](https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline). Accessed January 21, 2020.
11. Hill, B., et al., Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. *J Urol*, 2004. 171(6 Pt 1): p. 2336-40.
12. Larcher, A., et al., Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature. *Curr Urol Rep*, 2013. 14(6): p. 620-7.
13. McNicholas, T.A., et al., Minimally invasive prostatic urethral lift: surgical technique and multinational experience. *Eur Urol*, 2013. 64(2): p. 292-9.
14. McVary, K.T., et al., Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. *J Sex Med*, 2014. 11(1): p. 279-87.
15. NICE. Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. January 21, 2020; Available from: <https://www.nice.org.uk/guidance/ippg475>
16. NICE. Urolift for treating lower urinary tract symptoms of benign prostatic hyperplasia. Accessed January 21, 2020; Available from: <http://www.nice.org.uk/guidance/mtg26>
17. Perera, M., et al., Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol*, 2015. 67(4): p. 704-13.
18. Roehrborn, C.G., Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. *Rev Urol*, 2004. 6(3): p. 121-7.
19. Roehrborn, C.G., et al., Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology*, 2002. 60(3): p. 434-41.
20. Roehrborn, C.G., et al., Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REDuction by DUtasteride of prostate Cancer Events (REDUCE) trial. *Urology*, 2011. 78(3): p. 641-6.
21. Roehrborn, C.G., et al., The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol*, 2013. 190(6): p. 2161-7.
22. Roehrborn, C.G., et al., Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol*, 2015. 22(3): p. 7772-82.
23. Roehrborn CG, Barkin J, Gange SN, et al., Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol*, 2017. 24.3: 8802-8813.
24. Shore, N., et al., Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Can J Urol*, 2014. 21(1): p. 7094-101.
25. Sievert KD, Schonthaler M, Berges R, et al, Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. *World J Urology*, 2019. 37(7): 1353-1360.
26. Sonksen, J., et al., Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol*, 2015. 68(4): p. 643-52.
27. UroLift. The UroLift System. 2020; Available from: <http://www.urolift.com/physicians/procedure-device>
28. Woo, H.H., et al., Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med*, 2012. 9(2): p. 568-75.
29. Woo, H.H., et al., Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). *BJU Int*, 2011. 108(1): p. 82-8.
30. Wu, X.J., et al., Dutasteride on Benign Prostatic Hyperplasia: A Meta-analysis on Randomized Clinical Trials in 6460 Patients. *Urology*, 2014. 83(3): p. 539-43.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



VARICOCELE EMBOLIZATION

Policy # 612

Implementation Date: 10/3/17

Review Dates: 10/15/18, 10/15/19, 12/18/20, 12/8/21, 1/17/23, 10/19/23

Revision Dates: 11/7/23

Related Medical Policies:

[#268 Pelvic Vein Procedures for Pelvic Congestion Syndrome and Pelvic Varices](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Varicoceles (dilations of the pampiniform venous plexus) are found in 10 to 15% of the male population and they occur predominantly on the left side. The etiology may be a longer left spermatic vein with its right-angle insertion into the left renal vein and/or absence of valves, which results in a higher hydrostatic pressure in the left spermatic vein causing dilatation. Also, the left renal vein may be compressed between the superior mesenteric artery and the aorta. This "nutcracker phenomenon" may result in elevated pressure in the left testicular venous system. Moreover, the incidence of varicocele in men with impaired fertility is about 30%; varicoceles are the most common surgically correctable cause of male infertility. A clinical grading system classifies varicoceles into 3 grades, grade 1 (small)—palpable only during a Valsalva maneuver, grade 2 (moderate)—palpable without the need of the Valsalva maneuver, and grade 3 (large)—visible.

Although varicoceles can be diagnosed by a thorough physical examination, ultrasonography is the most practical and accurate non-invasive method in diagnosing this condition. Surgical ligation (varicocelectomy) is the conventional approach in managing varicoceles. However, percutaneous embolization by means of balloon or metallic coil has been shown to be a safe and effective alternative to ligation in treating varicoceles.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

A. Select Health covers microsurgical varicocelectomy as an acceptable alternative method of treating a varicocele when any of the following coverage criteria are met.

Coverage criteria for surgery (any one of the following must be met):

1. Adolescents with grade 2 or 3 varicoceles associated with ipsilateral testicular growth retardation (covered under the medical benefit); or
2. Scrotal pain associated with varicoceles (covered under medical benefit); or
3. Males with infertility problems who have decreased sperm motility and lower sperm concentrations (covered under fertility benefit).



Varicocele Embolization, continued

B. Select Health covers percutaneous embolization (by means of balloon or metallic coil) as medically necessary for the treatment of varicocele when the following criteria are met:

1. Meets one of the above criteria for surgery

OR

2. Post-surgical (ligation) recurrence of varicoceles

Select Health does NOT cover surgical treatment (ligation, embolization) for subclinical varicocele as it is considered experimental and investigational because of insufficient evidence to support its effectiveness.

Select Health does NOT cover endoluminal occlusion devices (e.g., the ArtVentive endoluminal occlusion system) as it is considered experimental and investigational for the treatment of varicoceles because their effectiveness has not been established.

Select Health Advantage (Medicare/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

Select Health Community Care (Medicaid)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

As it relates to fertility, Polito and colleagues in 2004 stated the impact of varicocele on male infertility is still controversial since its role on the impairment of semen quality has never been fully demonstrated. Their study included a series of 426 young adult males who underwent percutaneous treatment of varicocele. Their semen parameters were evaluated at baseline and 12 months after the procedure. They concluded that the correction of varicocele in young adults is not a major indication when semen alteration is the only clinical problem. This agrees with the findings of Nabi et al., also from 2004 who compared the semen quality in 102 men with or without pregnancy after percutaneous embolization of varicoceles in the management of infertility. They concluded that varicocele embolization is a technically feasible, minimally invasive, outpatient procedure that improves semen quality significantly in patients with a pre-embolization semen density of 10 to 30 million/ml. However, no correlation was found between the improvements in semen quality and the pregnancy rate.

In a systematic review and meta-analysis, Kim et al. in 2015 noted that recent meta-analysis by the Cochrane collaboration concluded that treatment of varicocele may improve an infertile couple's chance of pregnancy. However, there has been no consensus on the management of subclinical varicocele. These researchers determined the impact of varicocele treatment on semen parameters and pregnancy rate in men with subclinical varicocele. Although there was also no statistically significant difference in pregnancy rate (OR 1.29, 95% CI: 0.99 to 1.67), surgical treatment resulted in statistically significant improvements on forward progressive sperm motility (MD 3.94, 95% CI: 1.24 to 6.65). The authors concluded that there is insufficient evidence to allow final conclusions because the quality of included studies was very low and further research is needed.

Varicocele Embolization, continued

Percutaneous embolization versus laparoscopic varicoectomy was assessed by Bechara et al. in 2009 in patients with symptomatic varicoceles. Outcomes were assessed out to 5 years. Treatment outcome and hospital costs of these two minimally invasive treatment modalities were compared. Most parameters measured did not show significant difference including mean operative time, effectiveness, or recurrence. Embolization treatment was associated with a lower complication rate than laparoscopic repair (9.7% versus 16.3%, $p = 0.03$). They concluded both laparoscopic varicoectomy and coil embolization are effective treatment modalities for varicoceles. With lower treatment complication rates in the interventional treatment group, coil embolization of the testicular vein appears to offer treatment advantage compared with laparoscopic repair in patients with varicoceles.

These findings conflict with another study Ayeche-Diaz et al. in 2009, where they reviewed the records of 135 males (mean age of 12.8 years) over 7 years. The authors concluded their experience showed a high degree of relapses after embolization. Section of the spermatic vessels (including the artery) with no lymphatic preservation is highly effective but involves 27% post-surgical hydroceles, usually self-limiting (only 1 patient had to undergo surgery later), with no testicular atrophy or other complications. Embolization must be reserved for patients with 1 testicle or with bilateral disease.

Microsurgical Varicocelectomy: Kondoh et al., in 2010, stated surgical ligation for varicocele is primarily used in the management of male infertility patients. However, effectiveness of the ligation for painful varicocele is still controversial. These investigators reviewed records from 18 patients (average age of 17.8 years) who underwent varicocele ligation done for pain at the authors' institution from June 1999 to May 2010. The varicocele was on the left side and was grade III in 15 cases and grade II in 3 cases. The pain was classified into 3 types: discomfort, dull pain, and sharp pain. Microsurgical varicocelectomy was done with inguinal or subinguinal approach. Evaluation of post-operative pain was available in 17 patients, and 15 patients (88%) reported complete resolution of the pain with average follow-up durations of 11 months (3 to 53 months). The authors concluded that microsurgical varicocelectomy using the inguinal or subinguinal approach was an effective treatment modality for varicocele-associated pain.

In a study by Seo et al. in 2010, the improvement of seminal characteristics and pregnancy rates after microsurgical varicocelectomy in men with subclinical varicocele were evaluated. A total of 143 patients with a subclinical left-sided varicocele were included in this study. Patients who agreed to microsurgical varicocelectomy ($n = 25$, surgery group), medical treatment with L-carnitine ($n = 93$ drug group), and those who did not agree to any treatment ($n = 25$, observation group) were enrolled. Semen characteristics were re-evaluated twice 6 months after treatment. The natural pregnancy rates were estimated by telephone interview between 1 and 2 years after treatment. In the surgery group, sperm counts improved significantly after microsurgical varicocelectomy. In the drug group, however, sperm parameters did not significantly improve after treatment. Natural pregnancy rates were 60% in the surgery group, 34.5% in the drug group, and 18.7% in the observation group. The natural pregnancy rate of the surgery group was higher than the other groups, and there were statistically significant differences among the 3 groups. The authors concluded that surgical treatment is the best option for management of subclinical varicocele.

These findings were further validated in a prospective, non-masked, parallel-group randomized, controlled trial, by Abdel-Meguid et al. in 2011. They examined if varicocele treatment is superior or inferior to no treatment in male infertility from an evidence-based perspective. 132 married men, 20 to 39 years of age, who had experienced infertility greater than or equal to 1 year, had palpable (Grade 2) varicoceles, and with at least 1 impaired semen parameter (e.g., sperm concentration less than 20 million/ml, progressive motility less than 50%, or normal morphology less than 30%) were eligible. Exclusions included subclinical or recurrent varicoceles, normal semen parameters, and azoospermia. Participants were randomly allocated to observation (the control arm [CA]) or subinguinal microsurgical varicocelectomy (the treatment arm [TA]). Semen analyses were obtained at baseline (3 analyses) and at follow-up months 3, 6, 9, and 12. The mean of each sperm parameter at baseline and follow-ups were determined. These researchers measured the spontaneous pregnancy rate (the primary outcome), changes from baseline in mean semen parameters, and the occurrence of adverse events (AE-the secondary outcomes) during the 12-month follow-up; $p < 0.05$ was considered significant. In CA within-arm analysis, none of the semen parameters revealed significant changes from baseline (sperm concentration [$p = 0.18$], progressive motility [$p = 0.29$], and normal morphology [$p = 0.05$]). Conversely, in TA within-arm analysis, the mean of all semen parameters improved significantly in follow-up versus baseline ($p < 0.0001$). In between-arm analysis, all semen parameters improved significantly in the TA

Varicocele Embolization, continued

versus CA ($p < 0.0001$); no AEs were reported. The authors concluded these findings provided level 1b evidence of the superiority of varicocelectomy over observation in infertile men with palpable varicoceles and impaired semen quality, with increased odds of spontaneous pregnancy and improvements in semen characteristics within 1-year of follow-up.

Finally, Diegidio et al., in 2010, reviewed all the various techniques, and their results and efficiencies, to provide practicing urologists with some guidance for choice of technique. Pregnancy rates were highest with microsurgical subinguinal technique. Varicocele recurrence rates were lowest with microsurgical subinguinal technique. Hydrocele formation rates were lowest with microsurgical inguinal technique. Surgical complications were highest in the laparoscopic technique. Varicocelectomy by itself or in conjunction with in-vitro fertilization is cost-effective. The authors concluded that microsurgical subinguinal or microsurgical inguinal techniques offer best outcomes; and varicocelectomy is a cost-effective treatment modality for infertility.

The European Association of Urology (EAU)'s guidelines on pediatric urology (Tekgul et al., 2009) stated that for the treatment of varicocele in children and adolescents, surgical intervention is based on ligation or occlusion of the internal spermatic veins. Ligation is performed at different levels, inguinal (or subinguinal) microsurgical ligation, and suprainguinal ligation, using open or laparoscopic techniques. The advantage of the former is the lower invasiveness of the procedure, while the advantage of the latter is a considerably lower number of veins to be ligated and safety of the incidental division of the internal spermatic artery at the suprainguinal level. Moreover, lymphatic-sparing varicocelectomy is preferred to prevent hydrocele formation and testicular hypertrophy development and to achieve a better testicular function according to the luteinizing hormone-releasing hormone stimulation test. The methods of choice are subinguinal or inguinal microsurgical (microscopic) repairs, or suprainguinal open or laparoscopic lymphatic-sparing repairs.

Endoluminal Occlusion Device: The ArtVentive EOS device has been developed for percutaneous, peripheral occlusion of the peripheral arterial and venous vasculature. The system is comprised of an implantable occlusion device and a delivery catheter. At present, there are 2 device sizes, size 1 for target vessels ranging between 3.5 and 5.5 mm in diameter, and size 2 for target vessels 5.5 to 8.5 mm in diameter. Venbrux et al. in 2014 studied the ArtVentive endoluminal occlusion system (EOS), to occlude the spermatic vein in symptomatic males with varicoceles, to determine the safety and effectiveness of this new endoluminal occlusion device. The treatment group included 6 adult males, aged 22 to 34 years; 9 target vessels were occluded and a total of 20 devices were implanted in 6 subjects. The acute occlusion rate at the end of the procedure was 100%, occurring in 9 of 9 vessels. The spermatic veins of all patients remained occluded on venography at 30 days follow-up. Pain scores related to varicoceles decreased in 5 of 6 patients. The authors concluded that although they recognized this study was limited, initial experience indicated that the ArtVentive EOS is a safe and effective new device for occlusion of vessels (varicoceles). They stated that the device has potential applications in other clinical conditions requiring occlusion of veins or arteries; further studies have not been identified.

Billing/Coding Information

CPT CODES

37241	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)
55530	Excision of varicocele or ligation of spermatic veins for varicocele; (separate procedure)
55535	Excision of varicocele or ligation of spermatic veins for varicocele; abdominal approach
55540	Excision of varicocele or ligation of spermatic veins for varicocele; with hernia repair
55550	Laparoscopy, surgical, with ligation of spermatic veins for varicocele

HCPCS CODES

No specific codes identified

Varicocele Embolization, continued

Key References

1. Abdel-Meguid TA, Al-Sayyad A, Tayib A, Farsi HM. Does varicocele repair improve male infertility? An evidence-based perspective from a randomized, controlled trial. *Eur Urol*. 2011;59(3):455-461.
2. Alqahtani A, Yazbeck S, Dubois J, et al. Percutaneous embolization of varicocele in children: A Canadian experience. *J Pediatr Surg*. 2002;37(5):783-785.
3. Ayeche-Díaz A, Oscoz-Lizarbe M, Pérez-Martínez A, et al. Treatment of adolescent varicocele: Is percutaneous embolization better? *Cir Pediatr*. 2009;22(3):134-138.
4. Bechara CF, Weakley SM, Kougiyas P, et al. Percutaneous treatment of varicocele with microcoil embolization: Comparison of treatment outcome with laparoscopic varicocelectomy. *Vascular*. 2009;17 Suppl 3: S129-S136.
5. Broe, M. P., Ryan, J. P. C., Ryan, E. J., Murphy, D. J., Mulvin, D. W., Cantwell, C., & Brophy, D. P. Spermatic vein embolization as a treatment for symptomatic varicocele. *Can Urol Assoc J*. 2021 Nov; 15(11): E569-E573.
6. Comud F, Belin X, Amar E, et al. Varicocele: Strategies in diagnosis and treatment. *Eur Radiol*. 1999;9(3):536-545.
7. Demas BE, Hricak H, McClure RD. Varicoceles: Radiologic diagnosis and treatment. *Radiol Clin North Am*. 1991; 29(3):619-627.
8. Diegidio P, Jhaveri JK, Ghannam S, et al. Review of current varicocelectomy techniques and their outcomes. *BJU Int*. 2011;108(7):1157-1172.
9. Ding H, Tian J, Du W, et al. Open non-microsurgical, laparoscopic or open microsurgical varicocelectomy for male infertility: A meta-analysis of randomized controlled trials. *BJU Int*. 2012;110(10):1536-1542.
10. Esteves SC, Miyaoka R, Roque M, Agarwal A. Outcome of varicocele repair in men with nonobstructive azoospermia: Systematic review and meta-analysis. *Asian J Androl*. 2016;18(2):246-253.
11. Evers JL, Collins JA, Clarke J. Surgery or embolisation for varicocele in subfertile men. *Cochrane Database Syst Rev*. 2009;(1):CD000479.
12. Eyre RC. Evaluation of nonacute scrotal pathology in adult men. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed February 2016.
13. Favard, N., Moulin, M., Fauque, P., Bertaut, A., Favelier, S., Estivalet, L., ... Loffroy, R. Comparison of three different embolic materials for varicocele embolization: retrospective study of tolerance, radiation and recurrence rate. *Quant Imaging Med Surg*. 2015 Dec; 5(6): 806-814. doi: 10.3978/j.issn.2223-4292.2015.10.10
14. Ficarra V, Crestani A, Novara G, Mironi V. Varicocele repair for infertility: What is the evidence? *Curr Opin Urol*. 2012;22(6):489-494.
15. French DB, Desai NR, Agarwal A. Varicocele repair: Does it still have a role in infertility treatment? *Curr Opin Obstet Gynecol*. 2008;20(3):269-274.
16. Gat Y, Bachar GN, Everaert K, et al. Induction of spermatogenesis in azoospermic men after internal spermatic vein embolization for the treatment of varicocele. *Hum Reprod*. 2005;20(4):1013-1017. [https://www.fertstert.org/article/S0015-0282\(01\)02568-7/fulltext](https://www.fertstert.org/article/S0015-0282(01)02568-7/fulltext)
17. <https://www.auanet.org/guidelines/guidelines/male-infertility#x15007>
18. Kim HJ, Seo JT, Kim KJ, et al. Clinical significance of subclinical varicocelectomy in male infertility: Systematic review and meta-analysis. *Andrologia*. 2016;48(6):654-661.
19. Kondoh N, Nagai J, Yamamoto S. Clinical outcome of microsurgical varicocelectomy done for pain. *Hinyokika Kiyo*. 2010;56(12):683-686.
20. Kuroiwa T, Hasuo K, Yasumori K, et al. Transcatheter embolization of testicular vein for varicocele testis. *Acta Radiol*. 1991;32(4):311-314.
21. Li F, Yamaguchi K, Okada K, et al. Significant improvement of sperm DNA quality after microsurgical repair of varicocele. *Syst Biol Reprod Med*. 2012;58(5):274-27.
22. Li M, Wang Z, Li H. Laparoendoscopic single-site surgery varicocelectomy versus conventional laparoscopic varicocele ligation: A meta-analysis. *J Int Med Res*. 2016 Sep 29 [Epub ahead of print].
23. Liu, Q, Zhang, X, Zhou, F, Xi, X, Xinheng, X., Lian, S., & Lian, Q. Comparing Endovascular and Surgical Treatments for Varicocele: A Systematic Review and Meta-Analysis. *Journal of Vascular and Interventional Radiology*. 2022 Jul; 33(7):834-840.
24. Lukkariinen O, Hellstrom P, Leinonen S, Juntunen K. Is varicocele treatment useful? *Ann Chir Gynaecol*. 1997;86(1):40-44.
25. Masson P, Brannigan RE. The varicocele. *Urol Clin North Am*. 2014;41(1):129-144.
26. Nabi G, Asterlings S, Greene DR, Marsh RL. Percutaneous embolization of varicoceles: Outcomes and correlation of semen improvement with pregnancy. *Urology*. 2004;63(2):359-363.
27. Nasser, H. M., Hussein, A., Behairy, G., M., & Abdo, M. Impact of percutaneous embolization versus subinguinal microsurgical ligation on semen parameters in primary varicocele patients: comparative study. *Egyptian Journal of Radiology and Nuclear Medicine*. (2020); 51:249. <https://doi.org/10.1186/s43055-020-00370-4>.
28. Pajovic B, Radojevic N, Dimitrovski A, et al. Advantages of microsurgical varicocelectomy over conventional techniques. *Eur Rev Med Pharmacol Sci*. 2015;19(4):532-538.
29. Polito M Jr, Muzzonigro G, Centini R, et al. Percutaneous therapy of varicocele: Effects on semen parameters in young adults. *Urol Int*. 2004;72(2):150-153.
30. Practice Committee of the American Society for Reproductive Medicine; Society for Male Reproduction and Urology. Report on varicocele and infertility: A committee opinion. *Fertil Steril*. 2014;102(6):1556-1560.
31. Puneekar SV, Prem AR, Ridhorkar VR, et al. Post-surgical recurrent varicocele: Efficacy of internal spermatic venography and steel-coil embolization. *Br J Urol*. 1996;77(1):124-128.
32. Rivilla F, Casillas JG, Gallego J, Lezana AH. Percutaneous venography and embolization of the internal spermatic vein by spring coil for treatment of the left varicocele in children. *J Pediatr Surg*. 1995;30(4):523-527.
33. Rivilla F, Casillas JG. Testicular size following embolization therapy for paediatric left varicocele. *Scand J Urol Nephrol*. 1997;31(1):63-65.
34. Seo JT, Kim KT, Moon MH, Kim WT. The significance of microsurgical varicocelectomy in the treatment of subclinical varicocele. *Fertil Steril*. 2010;93(6):1907-1910.
35. Shi Q, Zhu H, Wang XS, et al. Comparison of 3 microsurgical approaches to the treatment of varicocele: Report of 120 cases. *Zhonghua Nan Ke Xue*. 2013;19(10):931-934.

Varicocele Embolization, continued

37. Shlansky-Goldberg RD, VanArsdalen KN, Rutter CM, et al. Percutaneous varicocele embolization versus surgical ligation for the treatment of infertility: Changes in seminal parameters and pregnancy outcomes. *J Vasc Interv Radiol.* 1997;8(5):759-767.
38. Showell MG, Mackenzie-Proctor R, Brown J, et al. Antioxidants for male subfertility. *Cochrane Database Syst Rev.* 2014;12:CD007411.
39. Shridharani, A., Owen, RC, Elkelany, OO, Kim, ED. The Significance of clinical guidelines on Adult Varicocele Detection and Management. *Asian Journal of Andrology* 2016 18, 269-275.
40. Sigman M, Howards SS. Male infertility. In: *Campbell's Urology*. 7th Ed. Vol. II. PC Walsh, et al., eds. Philadelphia, PA: W.B. Saunders Co.; 1998; Ch. 43:1287-1330.
41. Sivanathan C, Abernethy LJ. Retrograde embolisation of varicocele in the paediatric age group: A review of 10 years' practice. *Ann R Coll Surg Engl.* 2003;85(1):50-51.
42. Tay KH, Martin ML, Mayer AL, et al. Selective spermatic venography and varicocele embolization in men with circumaortic left renal veins. *J Vasc Interv Radiol.* 2002;13(7):739-742.
43. Tekgöl S, Riedmiller H, Gerharz E, et al. Guidelines on paediatric urology. Amheim, The Netherlands: European Association of Urology; 2009. Available at: http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/Paediatric_Urology.pdf. Accessed April 16, 2011.
44. Venbrux AC, Rudakov L, Plass A, et al. A new occlusion device: Application of the ArtVentive endoluminal occlusion system (EOS) – first in human clinical trial. *Cardiovasc Intervent Radiol.* 2014;37(1):85-93.
45. Wagner L, Tostain J, Comité Andrologie de l'Association Française d'Urologie. Varicocele and male infertility: AFU 2006 guidelines. *Prog Urol.* 2007;17(1):12-17.
46. Wang J, Xia SJ, Liu ZH, et al. Inguinal and subinguinal micro-varicocelectomy, the optimal surgical management of varicocele: A meta-analysis. *Asian J Androl.* 2015;17(1):74-80.
47. Wheatley JK, Bergman WA, Green B, Walther MM. Transvenous occlusion of clinical and subclinical varicoceles. *Urology.* 1991;37(4):362-365.
48. Zhang Z, Zheng SJ, Yu W, et al. Comparison of surgical effect and postoperative patient experience between laparoscopic single-site and conventional laparoscopic varicocelectomy: a systematic review and meta-analysis. *Asian J Androl.* 2017;19(2):248-255.
49. Zuckerman AM, Mitchell SE, Venbrux AC, et al. Percutaneous varicocele occlusion: Long-term follow-up. *J Vasc Interv Radiol.* 1994;5(2):315-319.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and of Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association